
<html lang="en"     class="pb-page"  data-request-id="c26caf58-9d6c-4e75-a69f-fd70b25e2f2a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.6b01290;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2017.60.issue-1;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding" /></meta><meta name="dc.Creator" content="Qiang  Wang" /></meta><meta name="dc.Creator" content="Feiyang  Liu" /></meta><meta name="dc.Creator" content="Beilei  Wang" /></meta><meta name="dc.Creator" content="Fengming  Zou" /></meta><meta name="dc.Creator" content="Ziping  Qi" /></meta><meta name="dc.Creator" content="Cheng  Chen" /></meta><meta name="dc.Creator" content="Kailin  Yu" /></meta><meta name="dc.Creator" content="Chen  Hu" /></meta><meta name="dc.Creator" content="Shuang  Qi" /></meta><meta name="dc.Creator" content="Wenchao  Wang" /></meta><meta name="dc.Creator" content="Zhenquan  Hu" /></meta><meta name="dc.Creator" content="Juan  Liu" /></meta><meta name="dc.Creator" content="Wei  Wang" /></meta><meta name="dc.Creator" content="Li  Wang" /></meta><meta name="dc.Creator" content="Qianmao  Liang" /></meta><meta name="dc.Creator" content="Shanchun  Zhang" /></meta><meta name="dc.Creator" content="Tao  Ren" /></meta><meta name="dc.Creator" content="Qingsong  Liu" /></meta><meta name="dc.Creator" content="Jing  Liu" /></meta><meta name="dc.Description" content="The discovery of a novel potent type II ABL/c-KIT dual kinase inhibitor compound 34 (CHMFL-ABL/KIT-155), which utilized a hydrogen bond formed by NH on the kinase backbone and carbonyl oxygen of 34..." /></meta><meta name="Description" content="The discovery of a novel potent type II ABL/c-KIT dual kinase inhibitor compound 34 (CHMFL-ABL/KIT-155), which utilized a hydrogen bond formed by NH on the kinase backbone and carbonyl oxygen of 34..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 14, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01290" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01290" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01290" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01290" /></link>
        
    
    

<title>Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01290" /></meta><meta property="og:title" content="Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0016.jpeg" /></meta><meta property="og:description" content="The discovery of a novel potent type II ABL/c-KIT dual kinase inhibitor compound 34 (CHMFL-ABL/KIT-155), which utilized a hydrogen bond formed by NH on the kinase backbone and carbonyl oxygen of 34 as a unique hinge binding, is described. 34 potently inhibited purified ABL (IC50: 46 nM) and c-KIT kinase (IC50: 75 nM) in the biochemical assays and displayed high selectivity (S Score (1) = 0.03) at the concentration of 1 μM among 468 kinases/mutants in KINOMEscan assay. It exhibited strong antiproliferative activities against BCR-ABL/c-KIT driven CML/GISTs cancer cell lines through blockage of the BCR-ABL/c-KIT mediated signaling pathways, arresting cell cycle progression and induction of apoptosis. 34 possessed a good oral PK property and effectively suppressed the tumor progression in the K562 (CML) and GIST-T1 (GISTs) cells mediated xenograft mouse model. The distinct hinge-binding mode of 34 provided a novel pharmacophore for expanding the chemical structure diversity for the type II kinase inhibitors discovery." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01290"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01290">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01290&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01290&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01290&amp;href=/doi/10.1021/acs.jmedchem.6b01290" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 273-289</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01237" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01310" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 4-Methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qiang++Wang">Qiang Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Feiyang++Liu">Feiyang Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beilei++Wang">Beilei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fengming++Zou">Fengming Zou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ziping++Qi">Ziping Qi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Chen">Cheng Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kailin++Yu">Kailin Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chen++Hu">Chen Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuang++Qi">Shuang Qi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenchao++Wang">Wenchao Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhenquan++Hu">Zhenquan Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juan++Liu">Juan Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Wang">Wei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Wang">Li Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qianmao++Liang">Qianmao Liang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shanchun++Zhang">Shanchun Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Ren">Tao Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingsong++Liu">Qingsong Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Liu">Jing Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">High Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Hefei Cosource Medicine Technology Co. Ltd., 358 Ganquan Road, Hefei, Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div><div class="corresp-info"><strong>*</strong>For Q.L.: phone, 86-551-65595161; E-mail, <a href="/cdn-cgi/l/email-protection#750406191c004c42351d1813195b14165b161b"><span class="__cf_email__" data-cfemail="cabbb9a6a3bff3fd8aa2a7aca6e4aba9e4a9a4">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For J.L.: phone, 86-551-65593186; E-mail, <a href="/cdn-cgi/l/email-protection#c3a9aaada4afaab683abaea5afeda2a0eda0ad"><span class="__cf_email__" data-cfemail="482221262f24213d0820252e2466292b662b26">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01290&amp;href=/doi/10.1021%2Facs.jmedchem.6b01290" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 273–289</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 30, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 August 2016</li><li><span class="item_label"><b>Published</b> online</span>14 December 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 January 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01290" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01290</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D273%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DQiang%2BWang%252C%2BFeiyang%2BLiu%252C%2BBeilei%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D1%26contentID%3Dacs.jmedchem.6b01290%26title%3DDiscovery%2Bof%2B4-Methyl-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529-3-%2528trifluoromethyl%2529phenyl%2529-3-%2528%25281-nicotinoylpiperidin-4-yl%2529oxy%2529benzamide%2B%2528CHMFL-ABL%252FKIT-155%2529%2Bas%2Ba%2BNovel%2BHighly%2BPotent%2BType%2BII%2BABL%252FKIT%2BDual%2BKinase%2BInhibitor%2Bwith%2Ba%2BDistinct%2BHinge%2BBinding%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D289%26publicationDate%3DJanuary%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01290"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1835</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01290" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Qiang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Feiyang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Beilei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Fengming&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Ziping&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Kailin&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Chen&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Shuang&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Wenchao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Zhenquan&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Qianmao&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Shanchun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Qingsong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;273-289&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01290&quot;},&quot;abstract&quot;:&quot;The discovery of a novel potent type II ABL/c-KIT dual kinase inhibitor compound 34 (CHMFL-ABL/KIT-155), which utilized a hydrogen bond formed by NH on the kinase backbone and carbonyl oxygen of 34 as a unique hinge binding, is described. 34 potently inhibited purified ABL (IC50: 46 nM) and c-KIT kinase (IC50: 75 nM) in the biochemical assays and displayed high selectivity (S Score (1) = 0.03) at the concentration of 1 μM among 468 kinases/mutants in KINOMEscan assay. It exhibited strong antiproliferative activities against BCR-ABL/c-KIT driven CML/GISTs cancer cell lines through blockage of the BCR-ABL/c-KIT mediated signaling pathways, arresting cell cycle progression and induction of apoptosis. 34 possessed a good oral PK property and effectively suppressed the tumor progression in the K562 (CML) and GIST-T1 (GISTs) cells mediated xenograft mouse model. The distinct hinge-binding mode of 34 provided a novel pharmacophore for expanding the chemical structure diversity for the type II kinase inhibitors disco&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01290&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01290" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01290&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01290" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01290&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01290" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01290&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01290&amp;href=/doi/10.1021/acs.jmedchem.6b01290" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01290" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01290" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01290%26sid%3Dliteratum%253Aachs%26pmid%3D27966954%26genre%3Darticle%26aulast%3DWang%26date%3D2017%26atitle%3DDiscovery%2Bof%2B4-Methyl-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529-3-%2528trifluoromethyl%2529phenyl%2529-3-%2528%25281-nicotinoylpiperidin-4-yl%2529oxy%2529benzamide%2B%2528CHMFL-ABL%252FKIT-155%2529%2Bas%2Ba%2BNovel%2BHighly%2BPotent%2BType%2BII%2BABL%252FKIT%2BDual%2BKinase%2BInhibitor%2Bwith%2Ba%2BDistinct%2BHinge%2BBinding%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D1%26spage%3D273%26epage%3D289%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/jmcmar.2017.60.issue-1/20170112/jmcmar.2017.60.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery of a novel potent type II ABL/c-KIT dual kinase inhibitor compound <b>34</b> (CHMFL-ABL/KIT-155), which utilized a hydrogen bond formed by NH on the kinase backbone and carbonyl oxygen of <b>34</b> as a unique hinge binding, is described. <b>34</b> potently inhibited purified ABL (IC<sub>50</sub>: 46 nM) and c-KIT kinase (IC<sub>50</sub>: 75 nM) in the biochemical assays and displayed high selectivity (S Score (1) = 0.03) at the concentration of 1 μM among 468 kinases/mutants in KINOMEscan assay. It exhibited strong antiproliferative activities against BCR-ABL/c-KIT driven CML/GISTs cancer cell lines through blockage of the BCR-ABL/c-KIT mediated signaling pathways, arresting cell cycle progression and induction of apoptosis. <b>34</b> possessed a good oral PK property and effectively suppressed the tumor progression in the K562 (CML) and GIST-T1 (GISTs) cells mediated xenograft mouse model. The distinct hinge-binding mode of <b>34</b> provided a novel pharmacophore for expanding the chemical structure diversity for the type II kinase inhibitors discovery.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Type II kinase inhibitors that are featured by binding to the “DFG-out” inactive conformation of the kinases are an important class of drugs for anticancer therapy. Currently among over 30 FDA approved kinase inhibitors, at least seven of them, such as <b>1</b> (imatinib, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a><b>2</b> (sorafenib),<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a><b>3</b> (nilotinib),<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a><b>4</b> (regorafenib),<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a><b>5</b> (cabozantinib),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a><b>6</b> (ponatinib),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and <b>7</b> (lenvatinib),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> are believed to exert their functions through type II binding mode.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> In the canonical DFG-out binding mode, type II kinase inhibitors usually share similar structural features, including a moiety forming a hydrogen bond at the hinge-binding site, a moiety (usually an amide, urea, or 1,3-diketone) providing two hydrogen bonds with the Glu in the c-Helix and the Asp in the DFG motif, as well as a hydrophobic tail accommodating the hydrophobic pocket formed upon “DFG-out” shift.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> As shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, the chemical structures that provide the two hydrogen bonds and the hydrophobic tails are diverse while the hinge-binding moieties seem to be quite conservative, e.g., the <i>N</i>-heteroaromatic rings in compounds <b>1</b>–<b>7</b>. There are a few exceptions, such as p38/Eph inhibitor <b>8</b> (BIRB796),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a><b>9</b> (PDK1 inhibitor MP7),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and DDR1 inhibitor <b>10</b> (DDR1-IN-1)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> that bear unusual hinge binding hydrogen bond donors, i.e., the oxygen of morpholine, the oxygen of benzene-fused urea, and the oxygen of cyclic amide, which have been demonstrated in the X-ray crystal structures. The hydrogen bond between the hinge-binding moieties of type II inhibitors and the specific amino acid residues in the kinase backbone hinge region is crucial and required for the inhibitory potency. Given the fact that the chemical diversity of the middle part and the hydrophobic tail have been extensively explored while the hydrogen bond formation mode in the hinge binding part is relatively less investigated, seeking for new hinge binding mode will help to expand the pharmacophore diversity of type II inhibitors, which will lead to the discovery of more novel type II kinase inhibitors.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative type II inhibitors with nitrogen-mediated hinge binding (<b>1</b>–<b>7</b>) and distinct oxygen-mediated hinge binding (<b>8</b>–<b>10</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Recently, we reported a potent type II ABL/PDGFR inhibitor <b>12</b> (CHMFL-074), which displayed a distinct hinge binding hydrogen bond formed by oxygen of amide in <b>12</b> and NH of amide on the ABL kinase backbone in the X-ray crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HU9">5HU9</a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> This encouraged us to explore extensively this novel pharmarcophore. Through a structure guided drug design approach, the medicinal chemistry effort led to the discovery of a potent type II ABL/c-KIT dual kinase inhibitor compound <b>34</b> (CHMFL-ABL/KIT-155), which exhibited a suitable biochemical and PK/PD profile in the in vitro and in vivo disease models of CML as well as GISTs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81838" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81838" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry and Structure–Activity Relationship (SAR) Investigation</h3><div class="NLM_p">As depicted in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B, compounds <b>11</b>–<b>39</b> were prepared following the synthetic route shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of discovery of compound <b>34</b> with distinct hinge binding. (A) X-ray cocrystal structure of compound <b>12</b> with ABL kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HU9">5HU9</a>). (B) Structure–activity relationship (SAR) investigation route leading to compound <b>34</b> (CHMFL-ABL/KIT-155).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of compounds <b>11</b> and <b>12</b> began from nucleophilic substitution reaction between <b>40a</b> and <i>tert</i>-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate, which provided <b>41a</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). After deprotection of the Boc group under acidic condition, subsequent amide coupling reaction with nicotinic acid afforded <b>43g</b>. Then hydrogenation of the nitro group followed by amide coupling reaction with corresponding benzoic acid derivatives furnished the final products <b>11</b> and <b>12</b>, respectively.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>11</b> and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, overnight; (b) 4 N HCl in EtOAc, rt, overnight; (c) nicotinic acid, HATU, DIPEA, DMF, rt, 2 h; (d) H<sub>2</sub>, Pd/C, EtOAc, rt, 6 h; (e) R3-COOH, HATU, DIPEA, DMF, rt, 2 h.</p></p></figure><div class="NLM_p">Compounds <b>13</b>–<b>39</b> were obtained following a five-step synthetic route (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Starting from R1 substituted nitrophenol analogues <b>40a</b>–<b>c</b>, a nucleophilic substitution reaction with Boc protected amines afforded <b>41a</b>–<b>f</b>. Reduction of the nitro group to amino group via palladium catalyzed hydrogenation followed by amide coupling reaction with the benzoic acid derivative offered <b>43a</b>–<b>f</b>. Removal of the Boc protection under acidic condition followed by amide coupling with varieties of carboxylic acids or nucleophilic substitution with different electrophiles provided desired compounds <b>13</b>–<b>39</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>13</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) for <b>41a</b>,<b>e</b>,<b>f</b>, <i>tert</i>-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate; for <b>41b</b>, <i>tert</i>-butyl 3-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate; for <b>41c</b>, <i>tert</i>-butyl 3-(((methylsulfonyl)oxy)methyl) azetidine-1-carboxylate; for <b>41d</b>, <i>tert</i>-butyl (2-bromoethyl)carbamate, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, overnight; (b) H<sub>2</sub>, Pd/C, EtOAc, rt, 6 h; (c) 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) benzoic acid, HATU, DIPEA, DMF, rt, 2 h; (d) 4 N HCl in EtOAc, rt, overnight; (e) for <b>13</b>–<b>36</b>, carboxylic acid derivatives, HATU, DIPEA, DMF, rt, 2 h; for <b>37</b>, benzenesulfonyl chloride, DIPEA, DMF, rt, 2 h; for <b>38</b>, 4-chloro-6,7-dimethoxyquinazoline; and for <b>39</b>, 2-chloropyrimidine, DIPEA, <i>n</i>-butyl alcohol, reflux, overnight.</p></p></figure><div class="NLM_p">BCR-ABL driven BaF3 based isogenic P210-BaF3 cell and c-KIT dependent TEL-c-KIT BaF3 cell were used to examine the SAR of the newly generated compounds by testing cell’s growth inhibition (GI<sub>50s</sub>) as the readout. We first fixed the hinge binding (R2) part as nicotinamide and varied the linker, R1, and R3 moieties (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Compared to compound <b>1</b>, replacement of the pyrimidine with piperidine ring in the linker part (<b>11</b>) lost potencies both to ABL and c-KIT kinases. However, compound <b>12</b> that possessed compound <b>6</b>’s tail gained desirable potencies against P210-BaF3 and TEL-c-KIT BaF3 cell lines. Therefore, the tail part (R3) was retained. For the subsequent optimization, we mainly focused on the linker, the flag methyl, and the hinge binding moieties. With the tail (R3), flag methyl (R1), and the head fixed, we first investigated the linker moiety. Changing the linker from piperidine to ethanamine (<b>13</b>), 3-methylpyrrolidine (<b>14</b>), and 3-methylazetidine (<b>15</b>) all resulted in significant activity loss. In addition, compounds <b>14</b> and <b>15</b> started to gain activity to IL-3 dependent parental-BaF3 cell line. The data showed that a chloro atom at R1 position (<b>16</b>) displayed a similar trend to methyl group (<b>12</b>) in activities, while a bulky methoxy group (<b>17</b>) lowered the potency against both ABL and c-KIT kinases.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Exploration Focused on the R1/R3/Linker Moieties<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">We next explored the hinge-binding moiety (R2) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Compared to nicotinamide (<b>12</b>), 2-(pyridin-3-yl)acetamide (<b>18</b>) lost activity to ABL and c-KIT kinase significantly. Smaller propionyl (<b>19</b>) and acryloyl group (<b>20</b>) as the head moieties largely reduced the potencies to ABL while the potencies to c-KIT were retained. Installation of <i>N</i>,<i>N</i>-dimethyl hydrophilic moiety on the head (<b>21</b>) lowered the potencies to micromole level both to ABL and c-KIT. Replacing the pyridine with a more hydrophobic benzene group (<b>22</b>) lost 4-fold activity against ABL and 2-fold against c-KIT kinase. Switching the nitrogen atom from 3-position to 2-position (<b>23</b>) and 4-position (<b>24</b>) increased about 2-fold potency to ABL kinase, meanwhile keeping the activity against c-KIT kinase. Replacement of pyridine with thiophene (<b>25</b>) started to inhibit the parental BaF3 cell, while furan-3-carbonyl (<b>26</b>) retained similar activity trends to compound <b>12</b>. Interestingly, quinoline-3-carbonyl (<b>27</b>), 2-fluoronicotinoyl (<b>28</b>), 5-chloronicotinoyl (<b>29</b>), 2-chloronicotinoyl (<b>30</b>), 2-methylnicotinoyl (<b>31</b>), 4-methylnicotinoyl (<b>32</b>), and 5-methylnicotinoyl (<b>33</b>) all displayed toxicities against parental BaF3 cells. However, 4-methylnicotinoyl (<b>34</b>) exhibited good selectivity window between the parental BaF3 cell and ABL/c-KIT engineered isogenic cells. Furthermore, <b>34</b> increased about 5-fold potency against ABL kinase (GI<sub>50</sub>: 0.033 μM) and retained the activity against c-KIT kinase (GI<sub>50</sub>: 0.149 μM) compared to compound <b>12</b>. 6-Oxo-1,6-dihydropyridine-3-carbonyl (<b>35</b>) lost activities significantly to both ABL and c-KIT kinases. 2-Aminopyrimidine-5-carbonyl (<b>36</b>) presented similar activities to compound <b>12</b> against ABL kinase (GI<sub>50</sub>: 0.168 μM) and c-KIT kinase (GI<sub>50</sub>: 0.20 μM), meanwhile keeping the selectivity window to parental BaF3 cell (GI<sub>50</sub>: > 10 μM). Replacement of the amide with sulfonamide (<b>37</b>) significantly lost activity to ABL kinase and started to gain toxicity to the parental BaF3 cell. Removing the amide linkage and installment of the heterocycles, i.e., quinazoline (<b>38</b>) and pyrimidine (<b>39</b>), directly to the piperidine linker either exhibited toxicity to the parental BaF3 cell or significantly lost activities to ABL and c-KIT kinases.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Exploration Focused on the Hinge Binding (R2) Moiety<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0015.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Biochemical and Cellular Property Evaluation</h3><div class="NLM_p">Because compounds <b>23</b>, <b>24</b>, and <b>32</b>–<b>34</b> exhibited inhibitory activities against ABL and/or cKIT kinase in the BaF3 isogenic cell-based assays, we then further tested them with the purified ABL1 and KIT kinases using Invitrogen’s Z’Lyte based biochemical activity assay and employed compound <b>1</b> as control. The results showed that compounds <b>23</b> (IC<sub>50</sub>: 30 nM), <b>24</b> (IC<sub>50</sub>: 7 nM), <b>33</b> (IC<sub>50</sub>: 6 nM), and <b>34</b> (IC<sub>50</sub>: 46 nM) possessed strong inhibitory potencies to ABL1 kinase, and all of them were more potent than <b>1</b> (IC<sub>50</sub>: 223 nM) (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). Interestingly, <b>32</b> did not show apparent inhibition to ABL1 kinase (IC<sub>50</sub>: 7252 nM), which was consistent with the narrow growth inhibition selectivity window observed between P210-BaF3 and parental BaF3 cells. For c-KIT kinase, these compounds all displayed submicromolar inhibitory activities and <b>34</b> was the most active one (IC<sub>50</sub>: 75 nM). On the basis of these data, we finally selected <b>34</b> as the potent ABL/c-KIT dual inhibitor for further characterization.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Activity and selectivity characterization of compound <b>34</b>. (A) Biochemical assay characterization of the inhibitory activities of <b>1</b>, <b>23</b>, <b>24</b>, and <b>32</b>–<b>34</b> against primary targets ABL1 and KIT kinases. (B) KINOMEscan profiling of <b>34</b> at a concentration of 1 μM against 468 kinases and its biochemical inhibitory activities to the selected kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next examined the kinome-wide selectivity profile of compound <b>34</b> with DiscoveRx’s KINOMEscan technology.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The results demonstrated that <b>34</b> possessed good selectivity (S score (1) = 0.03 at 1 μM) among the 468 kinases and mutants tested. Besides ABL1 and c-KIT kinases, <b>34</b> also displayed strong binding against BLK, CSF1R, DDR1/2, LCK, LOK, and PDGFRβ kinases (percent activity remaining less than 1% at 1 μM of the inhibitor) (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01290/suppl_file/jm6b01290_si_001.pdf" class="ext-link">Table 1</a>). Given the fact that KINOMEscan is a binding assay and may not fully reflect the inhibitory activities, we then used Invitrogen’s Z’Lyte based biochemical activity assay to further confirm these potential targets (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). Besides ABL1 and c-KIT kinases, <b>34</b> also presented significant inhibitory activities to BLK (IC<sub>50:</sub> 81 nM), CSF1R (IC<sub>50:</sub> 227 nM), DDR1 (IC<sub>50:</sub> 116 nM), DDR2 (IC<sub>50:</sub> 325 nM), LCK (IC<sub>50:</sub> 12 nM), and PDGFRβ (IC<sub>50:</sub> 80 nM) kinases. To further confirm these targets in the cellular context, we then tested <b>34</b> on these kinase dependent isogenic BaF3 cells. Interestingly, <b>34</b> only exhibited strong antiproliferation efficacy against PDGFRβ (GI<sub>50</sub>: 0.014 μM), PDGFRα (GI<sub>50</sub>: 0.012 μM, Invitrogen Biochemical IC<sub>50</sub> 16 nM) and VEGFR2 (GI<sub>50</sub>: 0.035 μM, Invitrogen Biochemical IC<sub>50</sub> 30 nM) kinases dependent cell lines (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Compound <b>34</b> presented no apparent growth inhibition to Tel-DDR1-BaF3 (GI<sub>50</sub>: 9.77 μM) and BCR-DDR2-BaF3 (GI<sub>50</sub>: 6.08 μM) cell lines and moderate inhibitions against Tel-BLK-BaF3 (GI<sub>50</sub>: 0.658 μM), Tel-CSF1R-BaF3 (GI<sub>50</sub>: 0.162 μM), and Tel-LCK-BaF3 (GI<sub>50</sub>: 0.386 μM), which indicated that in the cellular context <b>34</b> might not be very potent to BLK, DDR1/2, CSF1R, and LCK kinases. In addition, considering that BCR-ABL and c-KIT mutations are frequently observed in clinic and some of them are critical for the drug sensitivity, we also evaluated compound <b>34</b> against these mutants in the BaF3 isogenic cells (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The data demonstrated that compound <b>34</b> was more effective against most BCR-ABL mutations than compound <b>1</b>, including P210/H369P-BaF3, P210/M356T-BaF3, P210/F317L-BaF3, and P210/F317I-BaF3 but not active against P210/T315I-BaF3 (GI<sub>50</sub>: > 10 μM). For varieties of c-KIT mutations, compound <b>34</b> showed good inhibitory activities to c-Kit/V559D, c-Kit/L576P, and c-Kit/N822K but it was less potent to other mutants such as c-Kit/V559D/V654A, c-Kit/T670I/V559D, c-Kit/V654A-BaF3, Tel-c-Kit/T670I, and c-KIT/D816V, which displayed a similar trend to compound <b>1</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiproliferative Effects of Compounds <b>1</b> and <b>34</b> against a Panel of Isogenic BaF3 Cell Lines<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center"><b>1</b> (GI<sub>50</sub>: μM)</th><th class="colsep0 rowsep0" align="center"><b>34</b> (GI<sub>50</sub>: μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">parental BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-BLK-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.658 ± 0.056</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-DDR1-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">9.77 ± 0.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCR-DDR2-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">6.08 ± 0.043</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-CSF1R-BaF3</td><td class="colsep0 rowsep0" align="center">0.11 ± 0.055</td><td class="colsep0 rowsep0" align="center">0.162 ± 0.089</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-LCK-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.386 ± 0.025</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-PDGFRα-BaF3</td><td class="colsep0 rowsep0" align="center">0.034 ± 0.008</td><td class="colsep0 rowsep0" align="center">0.012 ± 0.00017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-PDGFRβ-BaF3</td><td class="colsep0 rowsep0" align="center">0.019 ± 0.007</td><td class="colsep0 rowsep0" align="center">0.014 ± 0.00021</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-VEGFR2-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.035 ± 0.00012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P210/T315I-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P210/Y253H-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.67 ± 0.067</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P210/H369P-BaF3</td><td class="colsep0 rowsep0" align="center">1.79 ± 0.177</td><td class="colsep0 rowsep0" align="center">0.98 ± 0.046</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P210/M356T-BaF3</td><td class="colsep0 rowsep0" align="center">0.625 ± 0.253</td><td class="colsep0 rowsep0" align="center">0.27 ± 0.064</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P210/F317L-BaF3</td><td class="colsep0 rowsep0" align="center">2.16 ± 0.039</td><td class="colsep0 rowsep0" align="center">0.67 ± 0.031</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P210/F317I-BaF3</td><td class="colsep0 rowsep0" align="center">0.85 ± 0.253</td><td class="colsep0 rowsep0" align="center">0.49 ± 0.021</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-cKit-BaF3</td><td class="colsep0 rowsep0" align="center">0.37 ± 0.031</td><td class="colsep0 rowsep0" align="center">0.149 ± 0.031</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-cKit/V559D-BaF3</td><td class="colsep0 rowsep0" align="center">0.039 ± 0.008</td><td class="colsep0 rowsep0" align="center">0.078 ± 0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-cKit/V559D/V654A-BaF3</td><td class="colsep0 rowsep0" align="center">3.0 ± 0.089</td><td class="colsep0 rowsep0" align="center">2.87 ± 0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-cKit/N822K-BaF3</td><td class="colsep0 rowsep0" align="center">1.29 ± 0.057</td><td class="colsep0 rowsep0" align="center">0.124 ± 0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-cKit/T670I/V559D-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.01 ± 0.007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-cKit/V654A-BaF3</td><td class="colsep0 rowsep0" align="center">2.49 ± 0.14</td><td class="colsep0 rowsep0" align="center">1.84 ± 0.021</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-cKit/L576P-BaF3</td><td class="colsep0 rowsep0" align="center">0.102 ± 0.048</td><td class="colsep0 rowsep0" align="center">0.221 ± 0.0012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-cKit/T670I-BaF3</td><td class="colsep0 rowsep0" align="center">6.67 ± 0.24</td><td class="colsep0 rowsep0" align="center">1.85 ± 0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-cKit/D816V-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">5.06 ± 0.012</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triple testing.</p></div></div></div><div class="NLM_p">We then tested compound <b>34</b> against a panel of established cancer cell lines (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Not surprisingly, it exhibited better antiproliferation activities than compound <b>1</b> in the BCR-ABL dependent CML cancer cell lines such as K562 (GI<sub>50</sub>: 0.027 μM), MEG-01 (GI<sub>50</sub>: 0.02 μM), and KU812 (GI<sub>50</sub>: 0.056 μM). It also potently inhibited the growth of c-KIT dependent GISTs cancer cell lines including GIST-T1 (GI<sub>50</sub>: 0.023 μM) and GIST-882 (GI<sub>50</sub>: 0.095 μM) but not c-KIT independent GIST-48B (GI<sub>50</sub>: 3.96 μM). In addition, compound <b>34</b> did not show potent inhibitory activities against FLT3-ITD dependent AML cell lines, i.e., MV4-11 (GI<sub>50</sub>: 8.14 μM) and MOLM-14 (GI<sub>50</sub>: 8.49 μM), as well as other leukemic cell lines such as U937 (GI<sub>50</sub>: 5.73 μM), HL-60 (GI<sub>50</sub>: 7.34 μM), and REC-1 (GI<sub>50</sub>: 3.47 μM). Compound <b>34</b> did not exhibit apparent inhibitory activity against the normal Chinese hamster ovary (CHO) cells (GI<sub>50</sub> > 10 μM) either, which indicated a good selectivity window between the cancer cells and normal cells.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Effects of Compounds <b>1</b> and <b>34</b> against a Panel of Established Cancer Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center"><b>1</b> (GI<sub>50</sub>: μM)</th><th class="colsep0 rowsep0" align="center"><b>34</b> (GI<sub>50</sub>: μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">K562</td><td class="colsep0 rowsep0" align="center">0.267 ± 0.01</td><td class="colsep0 rowsep0" align="center">0.027 ± 0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MEG-01</td><td class="colsep0 rowsep0" align="center">0.074 ± 0.008</td><td class="colsep0 rowsep0" align="center">0.02 ± 0.007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KU812</td><td class="colsep0 rowsep0" align="center">0.163 ± 0.012</td><td class="colsep0 rowsep0" align="center">0.056 ± 0.0009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-T1</td><td class="colsep0 rowsep0" align="center">0.008 ± 0.0002</td><td class="colsep0 rowsep0" align="center">0.023 ± 0.0007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-882</td><td class="colsep0 rowsep0" align="center">0.014 ± 0.0003</td><td class="colsep0 rowsep0" align="center">0.095 ± 0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-48B</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">3.96 ± 0.098</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MV4–11</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">8.14 ± 0.017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MOLM-14</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">8.49 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U937</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">5.73 ± 0.037</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">7.34 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">REC-1</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">3.47 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHO</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triple testing.</p></div></div></div><div class="NLM_p">To examine the binding mechanism of compound <b>34</b>, we docked the molecule into ABL1 and c-KIT kinases based on the reported high resolution (1.53 Å) cocrystal structure of compound <b>12</b> with ABL1 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HU9">5HU9</a>)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A,B). The modeling results revealed that compound <b>34</b> adopted a typical type II binding mode (DFG out conformation) both to ABL1 and c-KIT kinase, which was represented by two canonical hydrogen bonds formed by Glu286 (ABL1)/Glu640 (c-KIT) located in the c-Helix and Asp381 (ABL1 and c-KIT) located in the DFG motif with the amide bond (NHC═O) of the inhibitor. Intriguingly, compound <b>34</b> also exhibited a distinct hinge binding that utilized an amide oxygen atom to form the hydrogen bonds with Met318 in ABL kinase and Cys673 in c-KIT kinase. This was different from the classic hinge-binding mode of compounds <b>1</b>–<b>7</b>.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding modes of compound <b>34</b> in complex with ABL1 and c-KIT kinases. (A) Docking of <b>34</b> in complex with ABL1 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HU9">5HU9</a>). (B) Docking of <b>34</b> in complex with c-KIT kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We then examined compound <b>34</b>’s effects on the BCR-ABL mediated signaling pathways in K562, KU812, and MEG-01 cells (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). The results demonstrated that it potently inhibited BCR-ABL’s autophosphorylation at Y245 site in K562 cells (EC<sub>50</sub> < 100 nM) and displayed a better inhibitory activity than compound <b>1</b>. Compound <b>34</b> also significantly blocked the downstream signaling mediators such as pStat5, pCrkL, and pERK in K562 cells, which also exhibited stronger potency than <b>1</b>. Similar trends were observed in the BCR-ABL dependent CML cell lines KU812 and MEG-01, which further confirmed that <b>34</b> had strong inhibitory effects on the BCR-ABL mediated signaling pathways. In other experiments, compound <b>34</b> also potently inhibited the autophosphorylation of c-KIT at Y703, Y719, and Y823 sites in GIST-T1 and GIST-882 cells and displayed similar inhibitory activities to compound <b>1</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). Furthermore, <b>34</b> significantly blocked downstream signaling mediators such as pAKT, pStat3/5, pERK, pS6K, and pS6 in GIST-T1 and GIST-882 cells, which was similar to compound <b>1</b>. Meanwhile, <b>34</b> displayed little effect on c-KIT independent GIST-48B cells.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>1</b> and <b>34</b> on the signaling transduction pathways. (A) Effects of <b>1</b> and <b>34</b> on the BCR-ABL mediated signaling pathways in the BCR-ABL dependent CML cell lines (K562, KU812, and MEG-01). (B) Effects of <b>1</b> and <b>34</b> on the c-KIT mediated signaling pathways in the c-KIT dependent (GIST-T1 and GIST-882) and c-KIT independent (GIST-48B) cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, compound <b>34</b> could effectively arrest the cell cycle into the G0/G1 phase starting from a concentration of 0.3 μM in K562, KU812, and MEG-01 cells as well as GIST-T1 and GIST-882 cells but not GIST-48B cells (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Similar results were observed for compound <b>1</b> at 1 μM concentration. Furthermore, apparent apoptosis was observed in K562, KU812, MEG-01, GIST-T1, and GIST-882 cells but not in GIST-48B cells by examining the cleavage of PARP and caspase-3 proteins (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of compounds <b>1</b> and <b>34</b> on induction of cell cycle progression in (A) K562, KU812, and MEG-01 CML cells and (B) GIST-T1, GIST-882, and GIST-48B GISTs cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of compounds <b>1</b> and <b>34</b> on apoptosis in (A) K562, KU812, and MEG-01 CML cells and (B) GIST-T1, GIST882, and GIST-48B GISTs cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vivo PK/PD Evaluation</h3><div class="NLM_p">We next evaluated compound <b>34</b>’s PK properties in rats following intravenous and oral administration (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The data demonstrated that <b>34</b> possessed an acceptable bioavailability (<i>F</i> = 47.5%) and a suitable half-life (<i>T</i><sub>1/2</sub> = 2.83 h) for oral administration. In the CML K562 cells inoculated xenograft mouse model, oral administration of compound <b>34</b> showed dose-dependent tumor progression suppression without apparent toxicity (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A–C). A dosage of 100 mg/kg/day exhibited TGI (tumor growth inhibition) of 66.8%, which was better than compound <b>1</b> at the same dosage (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>D). Immunohistochemistry stain results demonstrated that compound <b>34</b> could dose dependently inhibit the cancer cell proliferation (Ki-67 stain) and induce the apoptosis (TUNEL stain) (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>E). Similarly, compound <b>34</b> could also dose dependently suppress the GIST-T1 cell mediated tumors in the xenograft mouse model with a TGI of 46.5% at a dosage of 100 mg/kg/day (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>A–E).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Characterization of Compound <b>34</b> in Sprague–Dawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">data</th><th class="colsep0 rowsep0" align="center" char="±">iv (1 mg/kg)</th><th class="colsep0 rowsep0" align="center">po (10 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–t</sub> (ng/mL·h)</td><td class="colsep0 rowsep0" align="char" char="±">510.308 ± 55.802</td><td class="colsep0 rowsep0" align="center">2422.086 ± 1644.633</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng/mL·h)</td><td class="colsep0 rowsep0" align="char" char="±">557.859 ± 58.155</td><td class="colsep0 rowsep0" align="center">2432.354 ± 1653.435</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>(0–t)</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">1.933 ± 0.222</td><td class="colsep0 rowsep0" align="center">5.746 ± 1.179</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char="±">825.144 ± 197.748</td><td class="colsep0 rowsep0" align="center">222.966 ± 114.288</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">0.017 ± 0</td><td class="colsep0 rowsep0" align="center">6 ± 0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">2.469 ± 0.466</td><td class="colsep0 rowsep0" align="center">2.828 ± 0.039</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="center">47.46</td></tr></tbody></table></div></div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>34</b>’s antitumor efficacy in K562 xenograft mouse model. Female nu/nu mice bearing established K562 tumor xenografts were treated with <b>34</b> at 25.0, 50.0, and 100 mg/kg/d dosage, 100 mg/kg/d imatinib, or vehicle. Daily oral administration was initiated when K562 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained four or five animals. Data, mean ± SEM, (A) body weight, and (B) tumor size measurements from K562 xenograft mice after <b>34</b> and imatinib administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 0, 25.0, 50.0, or 100 mg/kg/d <b>34</b> and 100 mg/kg/d imatinib treatment. (D) Comparison of the final tumor weight in each group after 28-day treatment period of <b>34</b> and imatinib. Numbers in columns indicate the mean tumor weight in each group. *<i>p</i> < 0.05. (E) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues with <b>34</b> treatment groups in comparison with the vehicle and imatinib treatment group. Note the specific nuclear staining of cells with morphology consistent with proliferation and apoptosis (E, blue arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>34</b>’s antitumor efficacy in GIST-T1 xenograft mouse model. Female nu/nu mice bearing established GIST-T1 tumor xenografts were treated with <b>34</b> at 25.0, 50.0, and 100 mg/kg/d dosage, or vehicle. Daily oral administration was initiated when GIST-T1 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained five animals. Data, mean ± SEM, (A) body weight, and (B) tumor size measurements from GIST-T1 xenograft mice after <b>34</b> administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 25.0, 50.0, or 100 mg/kg/d <b>34</b> or vehicle treatment. (D) Comparison of the final tumor weight in each group after 21-day treatment period of <b>34</b>. Numbers in columns indicate the mean tumor weight in each group. ns, <i>p</i> > 0.05, *<i>p</i> < 0.05, **<i>p</i> < 0.01. (E) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues with <b>34</b> treatment groups in comparison with the vehicle group. Note the specific nuclear staining of cells with morphology consistent with proliferation and apoptosis (E, blue arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51417" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51417" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">On the basis of structure-guided drug design and hybrid drug design approaches, we have discovered a type II kinase inhibitor <b>34</b> showing strong inhibitory potency to BCR-ABL, c-KIT etc kinases. Importantly, compound <b>34</b> adopted a distinct hinge binding mode that the amide oxygen served as the hinge binding hydrogen bond donor. This is different from classical hinge bindings and may bring more opportunities for new type II inhibitor discovery. In the following extensive biological characterization, <b>34</b> exhibited good activity and selectivity only with finite kinase targets. Compound <b>34</b> also potently inhibited VEGFR2, PDGFRα/β, DDR1, and CSF1-R kinases, which might contribute to its antitumor activity because PDGFRs and VEGFR2 play critical roles in angiogenesis.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> DDR1 kinase plays role in the tumor proliferation, migration, and invasion,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and CSF1-R is essential for cell survival, proliferation, and differentiation.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> However, it should be noted that these off-targets may also potentially induce the adverse events in the clinic context. It is also worthy to note that compound <b>34</b> was not active to imatinib-resistant BCR-ABL mutant T315I and c-KIT mutants such as V654A, D816V etc., which are important mutants observed in the clinic. Further detailed SAR study based on this pharmacophore is required for achievement of potency against those drug resistant mutants. Besides, the good PK profile and antitumor efficacy in vivo suggested that compound <b>34</b> might be a good potential drug candidate and currently it is under extensive preclinical evaluation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06188" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06188" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">All reagents and solvents were purchased from commercial sources and used as obtained. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded with a Bruker 400 NMR spectrometer and referenced to deuterium dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>) or deuterium chloroform (CDCl<sub>3</sub>). Chemical shifts are expressed in ppm. In the NMR tabulation, s indicates singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad peak. LC/MS were performed on an Agilent 6224 TOF using an ESI source coupled to an Agilent 1260 Infinity HPLC system operating in reverse mode with an Agilent Eclipse Plus C18 1.8 μm 3.0 mm × 50 mm column. Flash column chromatography was conducted using silica gel (Silicycle 40–64 μm). The purities of all compounds were determined to be above 95% by HPLC.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> <i>N</i>-(4-Methyl-3-((1-nicotinoylpiperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide (<b>11</b>)</h4><div class="NLM_p"><b>44g</b> (0.05 mmol, 15.6 mg), HATU (0.06 mmol, 23 mg), and DIPEA (0.075 mmol, 10 mg) were dissolved in 0.5 mL of DMF and cooled to 0 °C. Then 4-((4-methylpiperazin-1-yl)methyl)benzoic acid (0.06 mmol, 14 mg) was added to the system, and the mixture was stirred at room temperature for 2 h then extracted with EtOAc and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under vacuum, and the residue was purified by silica gel flash chromatography (DCM/MeOH = 10/1) to offer the product <b>12</b> (17.1 mg, 65%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 8.67 (s, 2H), 8.04–7.82 (m, 3H), 7.52 (s, 4H), 7.33 (d, <i>J</i> = 6.4 Hz, 1H), 7.13 (d, <i>J</i> = 5.8 Hz, 1H), 4.61 (s, 1H), 3.97–3.48 (m, 6H), 3.07–2.78 (m, 7H), 2.17 (s, 3H), 2.04 (s, 2H), 1.79 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 528.2891 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>12</b>–<b>36</b> were prepared following the synthetic procedure of <b>11</b>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> <i>N</i>-(4-Methyl-3-((1-nicotinoylpiperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>12</b>)</h4><div class="NLM_p last">Yield 69%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.42 (s, 1H), 8.64 (s, 2H), 8.26–8.24 (m, 2H), 7.91–7.86 (m, 2H), 7.51–7.47 (m, 2H), 7.31 (d, <i>J</i> = 7.6 Hz, 1H), 7.13 (d, <i>J</i> = 7.6 Hz, 1H), 4.59 (m, 1H), 3.83–3.52 (m, 6H), 2.66 (s, 8H), 2.37 (s, 3H), 2.15 (s, 3H), 1.98 (s, 2H), 1.75 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 595.2776 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> <i>N</i>-(2-(2-Methyl-5-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamido)phenoxy)ethyl)nicotinamide (<b>13</b>)</h4><div class="NLM_p last">Yield 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 9.04 (s, 1H), 8.97 (s, 1H), 8.72 (s, 1H), 8.28 (s, 3H), 7.93 (s, 1H), 7.53 (s, 2H), 7.30 (s, 1H), 7.13 (s, 1H), 4.14 (s, 2H), 3.76 (s, 4H), 2.94 (s, 4H), 2.58 (s, 7H), 2.14 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 556.2461 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>N</i>-(4-Methyl-3-((1-nicotinoylpyrrolidin-3-yl)methoxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>14</b>)</h4><div class="NLM_p last">Yield 76%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.73 (s, 1H), 8.65 (s, 1H), 8.25 (s, 2H), 7.95–7.91 (m, 2H), 7.45 (s, 2H), 7.36–7.17 (m, 1H), 7.19–6.88 (m, 1H), 4.09–3.82 (m, 2H), 3.81–3.36 (m, 6H), 2.87 (s, 4H), 2.74 (s, 1H), 2.67–2.49 (m, 7H), 2.15–2.04 (m, 4H), 1.84 (s, 1H). LC/MS (ESI, <i>m</i>/<i>z</i>): 596.2776 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-(4-Methyl-3-((1-nicotinoylazetidin-3-yl)methoxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>15</b>)</h4><div class="NLM_p last">Yield 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 9.02–8.69 (m, 2H), 8.26 (s, 2H), 8.02 (s, 1H), 7.91 (d, <i>J</i> = 7.5 Hz, 1H), 7.49 (s, 2H), 7.28 (d, <i>J</i> = 8.2 Hz, 1H), 7.11 (s, 1H), 4.53 (s, 1H), 4.28–3.82 (m, 4H), 3.74 (s, 2H), 3.35 (s, 1H), 3.12 (s, 1H), 2.90 (s, 4H), 2.56 (s, 7H), 2.08 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 582.2606 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(4-Chloro-3-((1-nicotinoylpiperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>16</b>)</h4><div class="NLM_p last">Yield 72%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.61 (s, 1H), 8.67 (s, 2H), 8.29 (s, 2H), 7.93 (m, 2H), 7.75 (s, 1H), 7.48 (m, 3H), 4.71 (s, 1H), 3.81–3.33 (m, 6H), 3.04–2.50(m, 11H), 2.03 (s, 2H), 1.82 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 616.2219 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-(4-Methoxy-3-((1-nicotinoylpiperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>17</b>)</h4><div class="NLM_p last">Yield 76%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 9.71 (s, 1H), 8.65 (s, 2H), 8.27 (s, 2H), 7.89 (s, 2H), 7.51 (s, 2H), 7.37 (s, 1H), 7.02 (s, 1H), 4.52 (s, 1H), 3.96–2.71 (m, 20H), 2.02 (s, 2H), 1.73 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 612.2712 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(4-Methyl-3-((1-(2-(pyridin-3-yl)acetyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>18</b>)</h4><div class="NLM_p last">Yield 66%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 8.44 (s, 2H), 8.25 (s, 2H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 7.64 (d, <i>J</i> = 7.6 Hz, 1H), 7.47 (s, 1H), 7.34 (s, 1H), 7.27 (d, <i>J</i> = 8.1 Hz, 1H), 7.13 (d, <i>J</i> = 8.1 Hz, 1H), 4.54 (s, 1H), 3.80–3.77 (m, 6H), 3.45 (s, 2H), 3.09 (s, 4H), 2.69 (s, 7H), 2.14 (s, 3H), 1.94 (s, 2H), 1.67 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 610.2933 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(4-Methyl-3-((1-propionylpiperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>19</b>)</h4><div class="NLM_p last">Yield 76%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.37 (s, 1H), 8.23 (s, 2H), 7.91 (d, <i>J</i> = 8.1 Hz, 1H), 7.48 (s, 1H), 7.28 (d, <i>J</i> = 7.9 Hz, 1H), 7.12 (d, <i>J</i> = 7.9 Hz, 1H), 4.54 (s, 1H), 3.69 (s, 4H), 3.64 (s, 2H), 2.49–2.17 (m, 13H), 2.14 (s, 3H), 1.93 (s, 2H), 1.66 (s, 2H), 1.06–0.92 (m, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 547.2830 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(3-((1-Acryloylpiperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>20</b>)</h4><div class="NLM_p last">Yield 82%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 8.23 (s, 1H), 8.21 (s, 1H), 7.92 (d, <i>J</i> = 7.2 Hz, 1H), 7.74 (s, 1H), 7.29 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 6.84 (m, 1H), 6.13 (d, <i>J</i> = 6.4 Hz, 1H), 5.69 (d, <i>J</i> = 10.4 Hz,1H),4.56 (m, 1H), 3.75–3.53 (m, 6H), 2.44 (s, 8H), 2.23 (s, 3H), 2.14 (s, 3H), 1.95 (s, 2H), 1.68 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 545.2666 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(3-((1-(2-(Dimethylamino)acetyl)piperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>21</b>)</h4><div class="NLM_p last">Yield 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 8.27 (s, 2H), 7.93 (s, 1H), 7.54 (s, 1H), 7.26 (d, <i>J</i> = 6.4 Hz, 2H), 7.14 (d, <i>J</i> = 8.4 Hz, 1H), 4.60 (s, 1H), 4.24 (s, 2H), 3.77 (s, 4H), 3.53 (s, 2H), 3.13–0.251 (m, 17H), 2.12(s, 3H), 2.01 (s, 2H), 1.79 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 576.3091 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-(3-((1-Benzoylpiperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>22</b>)</h4><div class="NLM_p last">Yield 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 8.24 (s, 2H), 7.90 (s, 1H), 7.46 (m, 6H), 7.28 (s, 1H), 7.13 (d, <i>J</i> = 7.4 Hz, 1H), 4.58 (s, 1H), 3.82–3.52 (m, 6H), 2.69–2.41 (s, 8H), 2.41 (s, 3H), 2.16 (s, 3H), 1.99 (s, 2H), 1.72 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 595.2826 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(4-Methyl-3-((1-picolinoylpiperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>23</b>)</h4><div class="NLM_p last">Yield 79%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 8.59 (d, <i>J</i> = 4.2 Hz, 1H), 8.27 (s, 2H), 7.93 (t, <i>J</i> = 7.6 Hz, 2H), 7.58 (d, <i>J</i> = 7.6 Hz, 1H), 7.52–7.41 (m, 2H), 7.29 (d, <i>J</i> = 8.1 Hz, 1H), 7.13 (d, <i>J</i> = 8.1 Hz, 1H), 4.61 (s, 1H), 3.86–3.57 (m, 6H), 3.05 (s, 4H), 2.64 (s, 7H) 2.16 (s, 3H), 2.01 (s, 2H), 1.75 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 596.2782 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>24</b>)</h4><div class="NLM_p last">Yield 76%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 8.67 (d, <i>J</i> = 5.0 Hz, 2H), 8.26 (s, 2H), 7.91 (d, <i>J</i> = 8.6 Hz, 1H), 7.50 (s, 1H), 7.43 (d, <i>J</i> = 4.8 Hz, 2H), 7.29 (d, <i>J</i> = 8.3 Hz, 1H), 7.13 (d, <i>J</i> = 7.8 Hz, 1H), 4.59 (s, 1H), 3.93–3.31 (m, 6H), 3.00 (s, 4H), 2.62–2.52 (m, 7H), 2.16 (s, 3H), 2.00 (s, 2H), 1.77 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 596.2781[M + H]<sup>+</sup>.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(4-Methyl-3-((1-(thiophene-3-carbonyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>25</b>)</h4><div class="NLM_p last">Yield 86%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 8.26 (s, 2H), 7.91 (d, <i>J</i> = 7.8 Hz, 1H), 7.81 (s, 1H), 7.62 (s, 1H), 7.49 (s, 1H), 7.36–7.01 (m, 3H), 4.59 (s, 1H), 3.5–3.10 (m, 6H), 2.94 (s, 4H), 2.59 (m, 7H), 2.16 (s, 3H), 1.99 (s, 2H), 1.74 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 601.2377 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-(3-((1-(Furan-2-carbonyl)piperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>26</b>)</h4><div class="NLM_p last">Yield 76%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.25 (s, 2H), 7.91 (d, <i>J</i> = 7.8 Hz, 1H), 7.84 (s, 1H), 7.50 (s, 1H), 7.29 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.00 (d, <i>J</i> = 3.3 Hz, 1H), 6.63 (s, 1H), 4.61 (s, 1H), 3.86–3.67 (m, 6H), 2.77–2.55 (m, 8H), 2.45 (s, 3H), 2.15 (s, 3H), 2.02 (s, 2H), 1.76 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 585.2618 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-(4-Methyl-3-((1-(quinoline-3-carbonyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>27</b>)</h4><div class="NLM_p last">Yield 69%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.95 (s, 1H), 8.51 (s, 1H), 8.24 (d, <i>J</i> = 6.4 Hz, 2H), 8.21–7.98 (m, 2H), 8.00–7.72 (m, 2H), 7.69 (t, <i>J</i> = 7.6 Hz, 1H), 7.51 (s, 1H), 7.29 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.2 Hz, 1H), 4.63 (s, 1H), 3.90–2.55 (m, 6H), 2.89 (s, 4H), 2.59–2.46 (s, 7H), 2.17 (s, 3H), 2.06 (s, 2H), 1.82 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 646.2920 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(3-((1-(2-Fluoronicotinoyl)piperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>28</b>)</h4><div class="NLM_p last">Yield 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.34 (s, 1H), 8.26 (s, 2H), 8.08 (s, 1H), 7.90 (s, 1H), 7.49 (s, 2H), 7.28 (s, 1H), 7.13 (d, <i>J</i> = 7.3 Hz, 1H), 4.60 (s, 1H), 3.83–2.57 (m, 17H), 2.16 (s, 3H), 2.02 (s, 2H), 1.72 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 614.2683 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(3-((1-(5-Chloronicotinoyl)piperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>29</b>)</h4><div class="NLM_p last">Yield 72%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 8.72 (s, 1H), 8.61 (s, 1H), 8.25 (s, 2H), 8.08 (s, 1H), 7.92 (s, 1H), 7.49 (s, 1H), 7.28 (s, 1H), 7.14 (s, 1H), 4.60 (s, 1H), 3.73–2.52 (m, 17H), 2.16 (s, 3H), 2.01 (s, 2H), 1.83 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 630.2389 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(3-((1-(2-Chloronicotinoyl)piperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>30</b>)</h4><div class="NLM_p last">Yield 66%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 8.48 (s, 1H), 8.24 (s, 2H), 8.01–7.77 (m, 2H), 7.52–7.49 (m, 2H), 7.27 (s, 1H), 7.13 (d, <i>J</i> = 5.7 Hz, 1H), 4.59 (s, 1H), 3.84–2.51 (m, 17H), 2.15 (s, 3H), 1.94 (s, 2H), 1.73 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 630.2376 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(4-Methyl-3-((1-(2-methylnicotinoyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>31</b>)</h4><div class="NLM_p last">Yield 61%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 8.50 (s, 1H), 8.26 (s, 2H), 7.90 (s, 1H), 7.67 (s, 1H), 7.49 (s, 1H), 7.27 (s, 2H), 7.13 (d, <i>J</i> = 7.8 Hz, 1H), 4.58 (s, 1H), 3.90–3.05 (m, 6H), 2.67 (s, 8H), 2.42 (s, 3H), 2.26–1.46 (m, 7H). LC/MS (ESI, <i>m</i>/<i>z</i>): 610.2936 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(4-Methyl-3-((1-(4-methylnicotinoyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>32</b>)</h4><div class="NLM_p last">Yield 66%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 8.47 (s, 1H), 8.42 (s, 1H), 8.24 (d, <i>J</i> = 9.4 Hz, 2H), 7.91 (d, <i>J</i> = 8.3 Hz, 1H), 7.48 (s, 1H), 7.38–7.21 (m, 2H), 7.13 (d, <i>J</i> = 6.8 Hz, 1H), 4.58 (s, 1H), 3.79–3.19 (m, 6H), 2.97 (m, 11H), 2.15 (s, 3H), 2.02 (s, 3H), 1.97–1.78 (m, 4H). LC/MS (ESI, <i>m</i>/<i>z</i>): 610.2936 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(4-Methyl-3-((1-(5-methylnicotinoyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>33</b>)</h4><div class="NLM_p last">Yield 76%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 8.49 (s, 1H), 8.44 (s, 1H), 8.25 (d, <i>J</i> = 6.6 Hz, 2H), 7.91 (d, <i>J</i> = 7.7 Hz, 1H), 7.69 (s, 1H), 7.49 (s, 1H), 7.29 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.2 Hz, 1H), 4.59 (s, 1H), 3.81–3.31 (m, 6H), 3.07–2.57 (m, 11H), 2.34 (s, 3H), 2.16 (s, 3H), 2.02 (s, 2H), 1.75 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 610.2921 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(4-Methyl-3-((1-(6-methylnicotinoyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>34</b>)</h4><div class="NLM_p last">Yield 72%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 8.51 (s, 1H), 8.25 (s, 2H), 7.91 (d, <i>J</i> = 6.6 Hz, 1H), 7.76 (d, <i>J</i> = 6.7 Hz, 1H), 7.49 (s, 1H), 7.31 (d, 7.8 Hz, 2H), 7.13 (d, <i>J</i> = 7.3 Hz, 1H), 4.59 (s, 1H), 3.67 (m, 6H), 2.94–2.59 (s, 14H), 2.16 (s, 3H), 2.02 (s, 2H), 1.76 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 610.2936 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-(4-Methyl-3-((1-(6-oxo-1,6-dihydropyridine-3-carbonyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>35</b>)</h4><div class="NLM_p last">Yield 78%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.94 (s, 1H), 10.46 (s, 1H), 8.31 (s, 2H), 7.96 (s, 1H), 7.59 (m, 3H), 7.33 (s, 1H), 7.17 (s, 1H), 6.39 (s, 1H), 4.62 (s, 1H), 3.78–3.34 (m, 6H), 2.97–2.50 (m, 11H), 2.19 (s, 3H), 2.02 (s, 2H), 1.77 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 612.2736 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(3-((1-(2-Aminopyrimidine-5-carbonyl)piperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>36</b>)</h4><div class="NLM_p last">Yield 79%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 8.35 (s, 2H), 8.26 (s, 2H), 7.91 (d, <i>J</i> = 8.4 Hz, 1H), 7.50 (s, 1H), 7.30 (d, <i>J</i> = 8.0 Hz, 1H), 7.13–7.10 (m, 3H), 4.59 (s, 1H), 3.74–3.54 (m, 6H), 2.89–2.54 (s, 11H), 2.15 (s, 3H), 1.95 (s, 2H), 1.76 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 612.2826 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(4-Methyl-3-((1-(phenylsulfonyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>37</b>)</h4><div class="NLM_p last"><b>44a</b> (0.05 mmol, 15.6 mg) and DIPEA (0.075 mmol, 10 mg) were dissolved in 0.5 mL of DMF, then benzenesulfonyl chloride (0.06 mmol, 10.6 mg) was added to the system. The mixture was stirred at room temperature for 2 h and then extracted with EtOAc and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under vacuum, and the residue was purified by silica gel flash chromatography (DCM/MeOH = 10/1) to offer the product <b>37</b> (18.9 mg, 60%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24 (s, 2H), 7.90 (d, <i>J</i> = 8.5 Hz, 1H), 7.72 (m, 5H), 7.39 (s, 1H), 7.23 (d, <i>J</i> = 7.8 Hz, 1H), 7.04 (d, <i>J</i> = 8.1 Hz, 1H), 4.43 (s, 1H), 3.76 (s, 2H), 3.21–2.67 (s, 15H), 1.97 (s, 2H), 1.81 (s, 5H). LC/MS (ESI, <i>m</i>/<i>z</i>): 631.2496 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(3-((1-(6,7-Dimethoxyquinazolin-4-yl)piperidin-4-yl)oxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>38</b>)</h4><div class="NLM_p"><b>44a</b> (0.05 mmol, 15.6 mg), 4-chloro-6,7-dimethoxyquinazoline (0.06 mmol, 13.4 mg) and DIPEA (0.075 mmol, 10 mg) were dissolved in 0.5 mL of <i>n</i>-butyl alcohol. The system was refluxed overnight then extracted with EtOAc and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under vacuum, and the residue was purified by silica gel flash chromatography (DCM/MeOH = 10/1) to offer the product <b>38</b> (25.8 mg, 76%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 8.55 (s, 1H), 8.24 (s, 2H), 7.92 (d, <i>J</i> = 7.5 Hz, 1H), 7.52 (s, 1H), 7.21–7.12 (m, 4H), 4.65 (s, 1H), 3.93–3.62 (m, 12H), 2.79–2.26 (s, 11H), 2.18 (s, 5H), 1.95 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 679.3146 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compound <b>39</b> were prepared following the synthetic procedure of <b>38</b>.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(4-Methyl-3-((1-(pyrimidin-2-yl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>39</b>)</h4><div class="NLM_p last">Yield 84%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.37 (s, 1H), 8.37 (d, <i>J</i> = 4.4 Hz, 2H), 8.24 (s, 2H), 7.92 (d, <i>J</i> = 7.5 Hz, 1H), 7.49 (s, 1H), 7.30 (d, <i>J</i> = 8.1 Hz, 1H), 7.13 (d, <i>J</i> = 7.6 Hz, 1H), 6.62 (s, 1H), 4.59 (s, 1H), 4.05 (s, 2H), 3.71 (s, 4H), 2.54–2.48 (m, 7H), 2.35 (s, 3H), 2.14 (s, 3H), 1.98 (s, 2H), 1.69 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 569.2783 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>tert</i>-Butyl 4-(5-Amino-2-methylphenoxy) piperidine-1-carboxylate (<b>42a</b>)</h4><div class="NLM_p"><b>40a</b> (5 mmol, 0.77 g) and <i>tert</i>-butyl 4-((methylsulfonyl)oxy) piperidine-1-carboxylate (10 mmol, 2.79 g) was dissolved in 15 mL of DMF, then K<sub>2</sub>CO<sub>3</sub> (10 mmol, 1.38 g) was added to the system and heated at 90 °C overnight. The reaction mixture was extracted with EtOAc and dried with anhydrous Na<sub>2</sub>SO<sub>4.</sub> The solvent was removed under vacuum, and the residue was purified by silica gel flash column chromatography (petroleum ether:EtOAc = 6:1) to give intermediate <b>41a</b> as a yellow solid. LC/MS (ESI, <i>m</i>/<i>z</i>): 359.1693 [M + Na]<sup>+</sup>. Then <b>41a</b> was directly dissolved in 20 mL of EtOAc and Pd/C (5%) was added. The mixture was stirred under hydrogen balloon at room temperature for 6 h. The system was filtered through diatomaceous earth, and the filtrate was concentrated under vacuum. The residue was purified by silica gel flash chromatography (petroleum ether:EtOAc = 8:1) to give the desired product <b>42a</b> (1.12 g, two-step yield: 73%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.74 (d, <i>J</i> = 6.0 Hz, 1H), 6.23 (s, 1H), 6.07 (d, <i>J</i> = 6.0 Hz, 1H), 4.78 (s, 2H), 4.37–4.35 (m, 1H), 3.55 (m, 2H), 3.26 (m, 2H), 1.97 (s, 3H), 1.83 (s, 2H), 1.55 (s, 2H), 1.40 (s, 9H). LC/MS (ESI, <i>m</i>/<i>z</i>): 329.1949 [M + Na]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>42b</b>–<b>f</b> were prepared following the synthetic procedure of <b>42a</b>.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>tert</i>-Butyl 3-((5-Amino-2-methylphenoxy)methyl)pyrrolidine-1-carboxylate (<b>42b</b>)</h4><div class="NLM_p last">Yield (two-step) 61%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.88 (s, 1H), 6.21–6.19 (m, 2H), 3.85 (s, 2H), 3.56–3.21 (m, 4H), 2.69–2.65 (m, 1H), 2.08 (s, 4H), 1.81 (m, 1H), 1.46 (s, 9H). LC/MS (ESI, <i>m</i>/<i>z</i>): 329.1952 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>tert</i>-Butyl 3-((5-Amino-2-methylphenoxy)methyl)azetidine-1-carboxylate (<b>42c</b>)</h4><div class="NLM_p last">Yield (two-step) 56%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.90 (s, 1H), 6.24–6.22 (m, 2H), 4.33–3.56 (m, 8H), 3.02–2.96 (m, 1H), 2.08 (s, 3H), 1.44 (s, 9H). LC/MS (ESI, <i>m</i>/<i>z</i>): 315.1793 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>tert</i>-Butyl (2-(5-Amino-2-methylphenoxy)ethyl)carbamate (<b>42d</b>)</h4><div class="NLM_p last">Yield (two-step) 59%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.95 (s, 1H), 6.74 (d, <i>J</i> = 7.7 Hz, 1H), 6.17 (s, 1H), 6.07 (d, <i>J</i> = 7.6 Hz, 1H), 4.82 (s, 2H), 3.82 (s, 2H), 3.30 (d, <i>J</i> = 5.5 Hz, 2H), 1.98 (s, 3H), 1.40 (s, 9H). LC/MS (ESI, <i>m</i>/<i>z</i>): 267.1626 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>tert</i>-Butyl 4-(5-Amino-2-chlorophenoxy)piperidine-1-carboxylate (<b>42e</b>)</h4><div class="NLM_p last">Yield (two-step) 71%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.09 (d, <i>J</i> = 7.6 Hz,1H), 6.29–6.23 (m, 2H), 4.32–4.28 (m, 1H), 3.64–3.62 (m, 2H), 3.46–3.42 (m, 2H), 1.82 (s, 4H), 1.45 (s, 9H). LC/MS (ESI, <i>m</i>/<i>z</i>): 349.1403 [M+ Na]<sup>+</sup>.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>tert</i>-Butyl 4-(5-Amino-2-methoxyphenoxy)piperidine-1-carboxylate (<b>42f</b>)</h4><div class="NLM_p last">Yield (two-step) 69%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.67 (d,<i>J</i> = 7.6 Hz,1H), 6.30 (s, 1H), 6.13 (d, <i>J</i> = 7.6 Hz,1H), 4.61 (s, 2H), 4.32–4.28 (m, 1H), 3.63–3.60 (m, 5H), 3.16 (s, 2H), 1.97 (s, 3H), 1.81 (s, 2H), 1.51 (s, 2H), 1.40 (s, 9H). LC/MS (ESI, <i>m</i>/<i>z</i>): 345.1898 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-(2-Methyl-5-nitrophenoxy)piperidine Hydrochloride (<b>42g</b>)</h4><div class="NLM_p last">Compound <b>41a</b> (5 mmol, 1.68 g) was added into 4 N HCl in EtOAc (20 mL), and the system was stirred at room temperature for 6 h. The solid was collected and dried to give the product <b>42g</b> as a yellow solid (1.22 g, 90%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.35 (s, 2H), 7.91–7.65 (m, 2H), 7.47 (d, <i>J</i> = 8.1 Hz, 1H), 4.92 (s, 1H), 3.16 (s, 4H), 2.29 (s, 3H), 2.17 (s, 2H), 1.95 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 237.1159 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(4-Methyl-3-(piperidin-4-yloxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide Trihydrochloride (<b>44a</b>)</h4><div class="NLM_p">To a solution of 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) benzoic acid (3 mmol, 906 mg) and <b>42a</b> (3 mmol, 918 mg) in 15 mL of DMF was added HATU (3.6 mmol, 1.37 g) and DIPEA (4.5 mmol, 585 mg). The mixture was stirred at room temperature for 2 h, and the system was quenched with water, extracted with EtOAc, and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvents were removed under vacuum to provide the crude product <b>43a</b>. LC/MS (ESI, <i>m</i>/<i>z</i>): 491.2565 [M + H]<sup>+</sup>. Then <b>43a</b> was directly dissolved in 4 N HCl in EtOAc (10 mL), and the mixture was stirred at room temperature overnight. The solid was collected and dried to give the product <b>44a</b> (915 mg, two-step yield 51%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.96 (s, 1H), 10.52 (s, 1H), 9.06 (s, 1H), 9.00 (s, 1H), 8.37–8.23 (m, 2H), 8.02 (s, 1H), 7.55 (s, 1H), 7.30 (d, <i>J</i> = 7.2 Hz, 1H), 7.15 (d, <i>J</i> = 6.3 Hz, 1H), 4.57 (s, 1H), 3.41–2.76 (m, 12H), 2.16–1.92 (m, 10H). LC/MS (ESI, <i>m</i>/<i>z</i>): 491.2565 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>44b</b>–<b>f</b> were prepared following the synthetic procedure of <b>44a</b>.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(4-Methyl-3-(pyrrolidin-3-ylmethoxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide Trihydrochloride (<b>44b</b>)</h4><div class="NLM_p last">Yield (two-step) 56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.58 (s, 1H), 10.57 (s, 1H), 9.55 (s, 2H), 8.36–8.19 (m, 3H), 7.51 (s, 1H), 7.31 (s, 1H), 7.11 (d, <i>J</i> = 5.2 Hz, 1H), 4.15 (s, 2H), 3.99 (s, 2H), 3.49–2.67 (m, 16H), 2.13 (s, 4H), 1.79 (s, 1H). LC/MS (ESI, <i>m</i>/<i>z</i>): 491.2569 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i>-(3-(Azetidin-3-ylmethoxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide Trihydrochloride (<b>44c</b>)</h4><div class="NLM_p last">Yield (two-step) 67%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.96 (s, 1H), 10.68 (s, 1H), 9.62 (s, 2H), 8.57 (s, 1H), 8.42 (s, 1H), 8.36 (s, 2H), 7.55 (s, 1H), 7.37 (s, 1H), 7.11 (d, <i>J</i> = 6.9 Hz, 1H), 4.32 (s, 2H), 4.13 (s, 2H), 4.00 (s, 2H), 3.87 (s, 2H), 3.56- 3.24 (m, 9H), 2.78 (s, 3H), 2.15 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 477.2409 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(3-(2-Aminoethoxy)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide Trihydrochloride (<b>44d</b>)</h4><div class="NLM_p last">Yield (two-step) 62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (s, 1H), 8.39 (s, 5H), 8.24 (s, 1H), 7.54 (s, 1H), 7.38 (s, 1H), 7.15 (s, 1H), 4.20 (s, 4H), 3.52–3.11 (m, 12H), 2.79 (s, 3H), 2.21 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 451.2231 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(4-Chloro-3-(piperidin-4-yloxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>44e</b>)</h4><div class="NLM_p last">Yield (two-step) 73%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.22 (s, 1H), 10.80 (s, 1H), 9.18 (s, 2H), 8.41 (s, 1H), 8.34 (s, 1H), 8.10 (s, 1H), 7.85 (s, 1H), 7.50 (s, 1H), 7.46 (s, 1H), 4.68 (s, 1H), 4.00 (s, 2H), 3.44 (s, 2H), 3.17 (d, <i>J</i> = 25.5 Hz, 8H), 2.77 (s, 5H), 2.18 (s, 2H), 1.98 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 511.2016 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(4-Methoxy-3-(piperidin-4-yloxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide Trihydrochloride (<b>44f</b>)</h4><div class="NLM_p last">Yield (two-step) 73%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.53 (s, 1H), 9.12 (s, 2H), 8.36–8.20 (m, 3H), 7.57 (s, 1H), 7.40 (s, 1H), 7.01 (d, <i>J</i> = 6.3 Hz, 1H), 4.47 (s, 1H), 4.22 (s, 2H), 3.87–2.68 (m, 18H), 2.09 (s, 2H), 1.88 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 507.2513 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (4-(5-Amino-2-methylphenoxy)piperidin-1-yl)(pyridin-3-yl)methanone (<b>44g</b>)</h4><div class="NLM_p last">To a solution of nicotinic acid (3 mmol, 369 mg) and <b>42g</b> (3 mmol, 816 mg) in DMF (15 mL) was added HATU (3.6 mmol, 1.37 g) and DIPEA (4.5 mmol, 585 mg). The resulting mixture was stirred at room temperature for 2 h, and the system was quenched with water, extracted with EtOAc, and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvents were removed under vacuum to provide the crude product <b>43g</b>, which was directly dissolved in EtOAc (20 mL) and Pd/C (5%) was added. The mixture was stirred under hydrogen balloon at room temperature for 6 h. The system was filtered through diatomaceous earth, and the filtrate was concentrated under vacuum to give the product <b>44g</b> (727 mg, two-step yield 78%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.65 (s, 2H), 7.88 (d, <i>J</i> = 7.5 Hz, 1H), 7.49 (dd, <i>J</i> = 7.5, 4.7 Hz, 1H), 6.77 (d, <i>J</i> = 7.8 Hz, 1H), 6.28 (s, 1H), 6.09 (d, <i>J</i> = 7.6 Hz, 1H), 4.87 (s, 2H), 4.49 (s, 1H), 3.96–3.38 (m, 4H), 2.02 (s, 5H), 1.72 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 312.1640 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> BaF3 Isogenic Cell Generation</h3><div class="NLM_p last">Retroviral constructs for fusion kinases were made based on the pMSCVpuro (Clontech) backbone. For TEL fusion vectors, the first 1 kb of human TEL gene with an artificial myristoylation sequence (MGCGCSSHPEDD) was cloned into pMSCVpuro retroviral vector, followed by a 3xFLAG tag sequence and a stop codon; for BCR fusion vectors, the first 2.8 kb coding region of p210 amplified from K562 cell line was used in fusion constructs. Then the kinase domain coding sequences were inserted in-frame between TEL/BCR and 3xFLAG sequences. All mutagenesis were performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer’s instructions. Retrovirus was packaged in HEK293T cells by transfecting kinase-fusion MSCV vectors together with two helper plasmids, virus supernatants were harvested 48 h after transfection and filtered before infection. Then BaF3 cells were infected with harvested virus supernatants using spinoculation protocol, and stable cell lines were obtained by puromycin selection for 48 h. A second selection in the absence of IL-3 was performed to obtain IL-3 independent cell lines that solely depend on the introduced kinase activities for cell proliferation.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Cell Lines and Cell Culture</h3><div class="NLM_p last">The K562 (CML), KU812 (CML), MEG-01 (CML), MV4-11 (AML), MOLM14 (AML), U937 (AML), REC-1 (human B-cell lymphoma cell), HL-60 (human promyelocytic leukemia cells), MEC-1 (CLL), CHL (hamster lung cell), and CHO (hamster ovary cell) cell lines were obtained from American Type Culture Collection (Manassas, VA). The human GIST-T1, GIST882, and GSIT48B cells were kindly provided by the Group of Professor Jonathan A. Fletcher, Brigham and Women’s Hospital in Boston, USA. All the cells were grown in a humidified incubator (Thermo, USA) at 37 °C under 5% CO<sub>2</sub>. GIST-T1, CHO cells were maintained in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin. MV4-11, GIST-882, and GIST-48B were grown in IMDM supplemented with 10% FBS, 1% penicillin/streptomycin. All the other cell lines and all the isogenic Ba/F3 cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium supported with 10% FBS and 1% penicillin/streptomycin. Adherent cells were grown in tissue culture flasks until they were 85–95% confluent prior to use. For suspension cells, cells were collected by spin down at 800 rpm/min for 5 min before use.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> ABL1 and c-KIT Protein Purification</h3><div class="NLM_p last">A construct encoding c-ABL residues 229–500 with a His tag was cloned into baculovirus expression vector pFASTHTA. The protein was expressed by infecting SF9 cells with high titer viral stocks for 48 h. Cells were harvested and lysed in 30 mM Tris pH7.4, 150 mM NaCl, 3 mM KCl, 10% glycerol, 1 mM PMSF, 2 mM TCEP, 1 mM ADP, and 20 mM imidazole. The supernatant was loaded to Ni-NTA column (QIAGEN, 1018244). Then the proteins were gradient washed using the same buffer with 50 mM and 100 mM imidazole, and then the ABL protein was eluted with elution buffer (20 mM Tris, 500 mM NaCl, 1% glycerol, 1 mM TCEP, 0.5 mM ADP, and 300 mM imidazole, pH 8.0). The eluted protein was loaded on desalt column PD-10(GE) to change the buffer to 20 mM Tris, 500 mM NaCl, 1% glycerol, and 2 mM TCEP, pH 8.0. The protein was concentrated to 1 mg/mL, and aliquots were frozen and stored at −80 °C.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Kinase Biochemical Assay</h3><div class="NLM_p last">The fluorescence resonance energy transfer-based Z’Lyte kinase assay (Invitrogen, USA) was used to evaluate the IC<sub>50</sub> value of <b>34</b> and imatinib for inhibition of ABL and KIT kinase. The reaction was performed on a 384-well plate with a 10 μL reaction volume per well containing 2 μM peptide (Tyr 02 peptide for ABL kinase, Tyr 06 peptide for KIT kinase) substrate in reaction buffer and ABL kinase (2.5 μL, 5 ng) or KIT kinase (2.5 μL, 10 ng) with a serial 3-fold dilution of <b>34</b> and imatinib (2.5 μL, 10 μM to 1.5 nM). The final reaction concentration of ATP was 300 μM. After 1 h incubation, a reaction was developed and terminated, and the fluorescence measured with an automated plate reader (SpectraMax I3, USA). A dose–response curve was fitted using Prism 5.0 (GraphPad Software Inc., San Diego, CA).</div></div><div id="sec99" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Anti-Proliferation Assays</h3><div class="NLM_p last">A density of 1–2.5 × 10<sup>4</sup> cells/mL cells were mixed with various concentrations of compounds, and then 100 μL was added to each well and incubated for 72 h. Cell viability was determined using the CellTiter-Glo (Promega, USA) or CCK-8 (Beboy, China). Both assays were performed according to the manufacturer instructions. For CellTiter-Glo assay, luminescence was determined in a multilabel reader (Envision, PerkinElmer, USA). For CCK-8 assay, absorbance was measured in a microplate reader (iMARK, Bio-Rad, USA) at 450 and 655 nm. Data were normalized to control group (DMSO-<i>d</i><sub>6</sub>). GI<sub>50</sub> were calculated using Prism 6.0 (GraphPad Software, San Diego, CA).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Signaling Pathway Study</h3><div class="NLM_p last">K562, KU812, MEG-01, GIST-T1, GIST-882, and GIST-48B cells were treated with DMSO, serially diluted compound <b>34</b>, and 1 μM imatinib for 2 h before immunoblotting. For immunoblotting, cells were washed with ice-cold phosphate buffered saline (PBS) and lysed using radio-immunoprecipitation (RIPA) buffer [150 mM NaCl, 1% (v/v) Nonidet P-40, 0.5% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) SDS] in 50 mM Tris HCl (pH8.0) supplemented with protease and phosphatase inhibitors (Thermo, USA; 1862209). Protein concentrations were determined using the BCA Protein Assay Kit (Beyotime, China; P0012) according to the manufacturer’s protocol. Proteins were separated by SDS-PAGE and transferred to an Immobilon-P PVDF membrane (Millipore, USA; IPVH00010) and blocked in 5% dry milk in Tris buffered saline, with Tween 20 (TBST). Membranes were incubated with primary and secondary antibodies, and target proteins were detected with ECL detection reagent (Pierce, USA; 32106). β-Actin (A5316) from Sigma-Aldrich was served as a loading control. Rabbit polyclonal antibodies to phospho-KIT Y823 was from Invitrogen (44-498G). Phospho-c-Abl (Tyr245) (73E5) rabbit mAb (2868), c-Abl antibody (2862), STAT5 (3H7) rabbit mAb (9358), Phospho-STAT5 (Tyr694) (C71E5) rabbit mAb (9314), Akt (pan) (C67E7) rabbit mAb (4691), Phospho-Akt (Thr308) (244F9) rabbit mAb (4056), Phospho-Akt (Ser473) (D9E) XP rabbit mAb (4060), Phospho-Crkl (Tyr207) antibody (3181), Crkl (32H4) mouse mAb (3182), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) rabbit mAb (4377), p44/42 MAPK (Erk1/2) (137F5) rabbit mAb (4695) antibodies, total c-KIT (3308), Phospho-KIT Y719 (3391), Phospho-KIT Y703 (3073), Phospho-Stat3 (9145), total Stat3 (12640), phospho-S6K T389 (9206), total S6K (9202), phospho-S6 S235/236 (2211), total S6 (2217), phospho-Src Y416 (6943), and total Src (2123) were obtained from Cell Signaling Technology (MA, USA).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Apoptosis Effect Examination</h3><div class="NLM_p last">K562, KU812, MEG-01, GIST-T1, GIST-882, and GIST-48B cells were treated with DMSO, serially diluted compound <b>34</b>, and 1 μM imatinib for indicated periods. Cells were collected and analyzed by Western blotting using following antibodies: PARP (9532) and caspase-3 (9665) from Cell Signaling Technology (MA, USA). β-Actin (A5316) served as a loading control.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Cell Cycle Analysis</h3><div class="NLM_p last">K562, KU812, MEG-01, GIST-T1, GIST-882, and GIST-48B cells were treated with serially diluted <b>34</b> for indicated periods. The cells were fixed in 70% cold ethanol and incubated at −20 °C overnight then stained with PI/RNase staining buffer (BD Pharmingen). Flow cytometry was performed using a FACS Calibur (BD), and results were analyzed by ModFit software.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> In Vivo Pharmacokinetics Study</h3><div class="NLM_p last">Compound <b>34</b> was dissolved in 55% saline containing 5% DMSO-<i>d</i><sub>6</sub> and 40% PEG400 by vortex. The final concentration of the stock solution was 1 mg/mL for administration. Six 8-week-old male Sprague–Dawley rats were fasted overnight before starting drug treatment via intravenous and oral administration. Animal blood collection time points were as follows. For groups 1, 3, and 5 (intravenous): 1 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 8 h before and after administration was selected. For groups 2, 4, and 6 (oral): 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h before and after dosing. Each time, about 0.2 mL of blood was collected through the jugular vein by adding heparin for anticoagulation and kept on ice. Then plasma was separated by centrifugation at 8000 rpm for 6 min at 2–8 °C. The obtained plasma was stored at −80 °C before analysis. After finishing the test, all surviving animals will be transferred to the repository or euthanasia (CO<sub>2</sub> asphyxiation).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> GIST-T1 Xenograft Tumor Model</h3><div class="NLM_p last">Four-week-old female nu/nu mice were purchased from the Shanghai Experimental Center, Chinese Academy of Sciences (Shanghai, China). All animals were maintained in a specific pathogen-free facility and used according to the animal care regulations of Hefei Institutes of Physical Science, Chinese Academy of Sciences (Hefei, China), and all efforts were made to minimize animal suffering. To obtain orthotopic xenograft of human mammary tumor in the mice, cells were harvested during exponential growth. Five million GIST-T1 cells in PBS were suspended in a 1:1 mixture with Matrigel (BD Biosciences) and injected into the subcutaneous space on the right flank of nu/nu mice. Daily oral administration was initiated when GIST-T1 tumors had reached a size of 200–400 mm<sup>3</sup>. Animals were then randomized into treatment groups of five mice each for efficacy studies. Compound <b>34</b> was delivered daily in a HKI solution (0.5% methylcellulose/0.4% Tween 80 in ddH<sub>2</sub>O) by oral gavages. A range of doses of <b>34</b> or its vehicle was administered, as indicated in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a> legends. Body weight and tumor growth was measured daily after <b>34</b> treatment. Tumor volumes were calculated as follows: tumor volume (mm<sup>3</sup>) = [(<i>W</i><sup>2</sup> × <i>L</i>)/2] in which width (<i>W</i>) is defined as the smaller of the two measurements and length (<i>L</i>) is defined as the larger of the two measurements.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> K562 Xenograft Tumor Model</h3><div class="NLM_p last">Five-week-old female nu/nu mice were purchased from the Shanghai Experimental Center, Chinese Science Academy (Shanghai, China). All animals were housed in a specific pathogen-free facility and used according to the animal care regulations of Hefei Institutes of Physical Science Chinese Academy of Sciences. Prior to implantation, cells were harvested during exponential growth. Ten million K562 cells in PBS were formulated as a 1:1 mixture with Matrigel (BD Biosciences) and injected into the subcutaneous space on the right flank of nu/nu mice. Daily oral administration was initiated when K562 tumors had reached a size of 200–400 mm<sup>3</sup>. Animals were then randomized into treatment groups of four or five mice each for efficacy studies. <b>34</b> was delivered daily in a HKI solution (0.5% methylcellulose/0.4% Tween 80 in ddH<sub>2</sub>O) by oral gavage. A range of doses of <b>34</b> or its vehicle were administered, as indicated in figure legends. Body weight and tumor growth was measured daily after <b>34</b> treatment. Tumor volumes were calculated as follows: tumor volume (mm<sup>3</sup>) = [(<i>W</i><sup>2</sup> × <i>L</i>)/2] in which width (<i>W</i>) is defined as the smaller of the two measurements and length (<i>L</i>) is defined as the larger of the two measurements.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Immunohistochemistry Stain</h3><div class="NLM_p last">Tumor tissues were fixed in 10% neutral-buffered formalin and embedded in paraffin. Six-micrometer tissue sections were prepared, deparaffinized, dehydrated, and then stained with hematoxylin and eosin (H&E) using routine methods. Commercially available primary antibody to human Ki-67 (ZSGB-BIO, Beijing, China) was used for Ki-67 staining. After heat-induced antigen retrieval, formalin-fixed and paraffin-embedded tumor tissue sections were stained with primary antibody overnight at 4 °C. The slides were subsequently incubated with ImmPRES antimouse Ig (Vector Laboratories, Burlingame, CA) at room temperature for 30 min, stained with peroxidase substrate 3,3′-diaminobenzidine chromogen (Vector Laboratories), and finally counterstained with hematoxylin. TUNEL staining was assessed using an In Situ Cell Death Detection Kit (POD) (Roche, Mannheim, Germany) according to the manufacturer’s instructions.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Molecular Modeling</h3><div class="NLM_p last">Molecular docking of compound <b>34</b> to the ABL1 kinase and the c-KIT kinase was performed with software Yeti<sup>X</sup> 8.3.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The kinase domain of chain A in the PDB were used for docking (PDBs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HU9">5HU9</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a> for ABL1 and c-KIT, respectively). Alternative conformations of the side chains were manually confirmed, and missing side chains were automatically added using AmberTools. The protonation and tautomeric state at physiological pH were confirmed by software Reduce,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and the receptor side chain structure was further optimized using Yeti<sup>X</sup> 8.3. Compound <b>34</b> was constructed using Bio<sup>X</sup> 4.6,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and the atomic partial charges were calculated by AmberTools. Template-based induced-fit docking of small molecules to the two kinases: ABL1 and c-KIT were performed using Yeti<sup>X</sup> 8.3. The docked modes were optimized by the directional <i>Yeti</i> force field.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01290">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02436" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02436" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01290" class="ext-link">10.1021/acs.jmedchem.6b01290</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">DiscoveRx’s KINOMEscan selectivity profiling data of compound <b>34</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01290/suppl_file/jm6b01290_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01290/suppl_file/jm6b01290_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01290/suppl_file/jm6b01290_si_001.pdf">jm6b01290_si_001.pdf (166.81 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01290/suppl_file/jm6b01290_si_002.csv">jm6b01290_si_002.csv (6.21 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01290" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingsong Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5120223d3824686611393c373d7f30327f323f"><span class="__cf_email__" data-cfemail="f687859a9f83cfc1b69e9b909ad89795d89598">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link">http://orcid.org/0000-0001-9513-3591</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#680201060f04011d2800050e0446090b460b06"><span class="__cf_email__" data-cfemail="7f1516111813160a3f17121913511e1c511c11">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiang Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feiyang Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beilei Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengming Zou</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziping Qi</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Chen</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kailin Yu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen Hu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuang Qi</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenchao Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenquan Hu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qianmao Liang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shanchun Zhang</span> - <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Hefei
Cosource Medicine Technology Co. Ltd., 358 Ganquan Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Ren</span> - <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. Q.W., F.L., B.W., F.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Dr. Shanchun Zhang is a shareholder of Hefei Cosource Medicine Technology Co. LTD.<br /></br></div></li></ul></div><div class="ack" id="ACK-d169e4092-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38173" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38173" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Q.L. is supported by the Joint Funds of Research on Major Science Facilities, Key Program of the National NSFC (no. U1432250) and the CAS/SAFEA international partnership program for creative research teams. J.L. is supported by the “Personalized Medicines—Molecular Signature-Based Drug Discovery and Development”, Strategic Priority Research Program of the Chinese Academy of Sciences (grant no. XDA12020308) and the National Program for Support of Top-notch Young Professionals. W.W., J.L., and Q.L. are supported by the “Cross-disciplinary Collaborative Teams Program for Science, Technology, and Innovation (2014-2016)” of Chinese Academy of Sciences. We are grateful for the China “Thousand Talents Program” support for Q.L. and “Hundred Talents Program” of the Chinese Academy of Sciences support for J.L. and W.W. Q.W. is supported by the National Natural Science Foundation of China (No. 81602973).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i75" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i75"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i76" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i76"> Abbreviations Used</h2><tr><td class="NLM_term">BCR-ABL</td><td class="NLM_def"><p class="first last">breakpoint cluster region-Abelson murine leukemia viral oncogene</p></td></tr><tr><td class="NLM_term">KIT</td><td class="NLM_def"><p class="first last">v-kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homologue</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myelogenous leukemia</p></td></tr><tr><td class="NLM_term">GISTs</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumors</p></td></tr><tr><td class="NLM_term">BLK</td><td class="NLM_def"><p class="first last">B lymphocyte kinase</p></td></tr><tr><td class="NLM_term">CSF1R</td><td class="NLM_def"><p class="first last">colony stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">DDR1/2</td><td class="NLM_def"><p class="first last">discoidin domain receptor 1/2</p></td></tr><tr><td class="NLM_term">LCK</td><td class="NLM_def"><p class="first last">lymphocyte-specific protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">LOK</td><td class="NLM_def"><p class="first last">lymphocyte oriented kinase</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">TUNEL</td><td class="NLM_def"><p class="first last">terminal deoxynucleotidyl transferase dUTP nick end labeling</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 22 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span><span class="refDoi"> DOI: 10.1126/science.289.5486.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+abelson+tyrosine+kinase&doi=10.1126%2Fscience.289.5486.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0li1Kyahu2Icwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942%26doi%3D10.1126%2Fscience.289.5486.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulfert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">13286</span><span class="NLM_x">–</span> <span class="NLM_lpage">13296</span><span class="refDoi"> DOI: 10.1021/ja902010p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja902010p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1ensrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=13286-13296&author=J.+R.+Simardauthor=M.+Getlikauthor=C.+Grutterauthor=V.+Pawarauthor=S.+Wulfertauthor=M.+Rabillerauthor=D.+Rauh&title=Development+of+a+fluorescent-tagged+kinase+assay+system+for+the+detection+and+characterization+of+allosteric+kinase+inhibitors&doi=10.1021%2Fja902010p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors</span></div><div class="casAuthors">Simard, Jeffrey R.; Getlik, Matthaus; Grutter, Christian; Pawar, Vijaykumar; Wulfert, Sabine; Rabiller, Matthias; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">13286-13296</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinase disregulation disrupts the intricate network of intracellular signaling pathways and contributes to the onset of diseases such as cancer.  Although several kinase inhibitors are on the market, inhibitor selectivity and drug resistance mutations persist as fundamental challenges in the development of effective long-term treatments.  Chem. entities binding to less conserved allosteric sites would be expected to offer new opportunities for scaffold development.  Because no high-throughput method was previously available, a fluorescence-based kinase binding assay for identifying and characterizing ligands which stabilize the inactive kinase conformation was developed.  Here, a description of the development and validation of this assay using the serine/threonine kinase p38α is presented.  The covalent attachment of fluorophores to the activation loop of the kinase allowed to detect the conformational changes and measure the Kd, kon, and koff assocd. with the binding and dissocn. of ligands to the allosteric pocket.  The SAR of a synthesized focused library of pyrazolourea derivs., a scaffold known to bind with high affinity to the allosteric pocket of p38α, is also reported.  Addnl., the protein X-ray crystallog. was used together with this assay to examine the binding and dissocn. kinetics to characterize potent quinazoline- and quinoline-based type II inhibitors, which also utilize this binding pocket in p38α.  Last, the b-Raf inhibitor sorafenib was identified as a potent low nanomolar inhibitor of p38α and the protein X-ray crystallog. was used to confirm its unique binding mode to the inactive kinase conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVNeYPzX2CHbVg90H21EOLACvtfcHk0lh8yV4wRMncIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1ensrk%253D&md5=f56e476572c7cdfb3411eb95b9759fca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fja902010p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja902010p%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DWulfert%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520a%2520fluorescent-tagged%2520kinase%2520assay%2520system%2520for%2520the%2520detection%2520and%2520characterization%2520of%2520allosteric%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D13286%26epage%3D13296%26doi%3D10.1021%2Fja902010p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.ccr.2005.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl&doi=10.1016%2Fj.ccr.2005.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lh8yV4wRMncIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141%26doi%3D10.1016%2Fj.ccr.2005.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zopf, D.</span><span> </span><span class="NLM_article-title">Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1002/ijc.25864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1002%2Fijc.25864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=21170960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=245-255&author=S.+M.+Wilhelmauthor=J.+Dumasauthor=L.+Adnaneauthor=M.+Lynchauthor=C.+A.+Carterauthor=G.+Schutzauthor=K.+H.+Thierauchauthor=D.+Zopf&title=Regorafenib+%28BAY+73%E2%80%934506%29%3A+a+new+oral+multikinase+inhibitor+of+angiogenic%2C+stromal+and+oncogenic+receptor+tyrosine+kinases+with+potent+preclinical+antitumor+activity&doi=10.1002%2Fijc.25864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span></div><div class="casAuthors">Wilhelm, Scott M.; Dumas, Jacques; Adnane, Lila; Lynch, Mark; Carter, Christopher A.; Schuetz, Gunnar; Thierauch, Karl-Heinz; Zopf, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-255</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Angiogenesis, a crit. driver of tumor development, is controlled by interconnected signaling pathways.  Vascular endothelial growth factor receptor (VEGFR) 2 and tyrosine kinase with Ig and epidermal growth factor homol. domain 2 play crucial roles in the biol. of normal and tumor vasculature.  Regorafenib (BAY 73-4506), a novel oral multikinase inhibitor, potently inhibits these endothelial cell kinases in biochem. and cellular kinase phosphorylation assays.  Furthermore, regorafenib inhibits addnl. angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF.  The antiangiogenic effect of regorafenib was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging.  Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts.  In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 h after the last dosing and correlated with tumor growth inhibition (TGI).  A significant redn. in tumor microvessel area was obsd. in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg.  Regorafenib exhibited potent dose-dependent TGI in various preclin. human xenograft models in mice, with tumor shrinkages obsd. in breast MDA-MB-231 and renal 786-O carcinoma models.  Pharmacodynamic analyses of the breast model revealed strong redn. in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2.  These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQpQXfCq04rVg90H21EOLACvtfcHk0lgTpgio-q3iAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D&md5=13eee29ef1f1f03fd1ed311ea613f566</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fijc.25864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25864%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DSchutz%26aufirst%3DG.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26aulast%3DZopf%26aufirst%3DD.%26atitle%3DRegorafenib%2520%2528BAY%252073%25E2%2580%25934506%2529%253A%2520a%2520new%2520oral%2520multikinase%2520inhibitor%2520of%2520angiogenic%252C%2520stromal%2520and%2520oncogenic%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520preclinical%2520antitumor%2520activity%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D245%26epage%3D255%26doi%3D10.1002%2Fijc.25864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">You, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennino, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcón, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashizume, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aftab, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcdonald, D. M.</span><span> </span><span class="NLM_article-title">VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4758</span><span class="NLM_x">–</span> <span class="NLM_lpage">4768</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1158%2F0008-5472.CAN-10-2527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4758-4768&author=W.+K.+Youauthor=B.+Senninoauthor=C.+W.+Williamsonauthor=B.+Falc%C3%B3nauthor=H.+Hashizumeauthor=L.+C.+Yaoauthor=D.+T.+Aftabauthor=D.+M.+Mcdonald&title=VEGF+and+c-Met+blockade+amplify+angiogenesis+inhibition+in+pancreatic+islet+cancer&doi=10.1158%2F0008-5472.CAN-10-2527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2527%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DW.%2BK.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DWilliamson%26aufirst%3DC.%2BW.%26aulast%3DFalc%25C3%25B3n%26aufirst%3DB.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DL.%2BC.%26aulast%3DAftab%26aufirst%3DD.%2BT.%26aulast%3DMcdonald%26aufirst%3DD.%2BM.%26atitle%3DVEGF%2520and%2520c-Met%2520blockade%2520amplify%2520angiogenesis%2520inhibition%2520in%2520pancreatic%2520islet%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4758%26epage%3D4768%26doi%3D10.1158%2F0008-5472.CAN-10-2527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2010.01054.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1111%2Fj.1747-0285.2010.01054.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=21118377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FitVymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2011&pages=1-11&author=T.+Zhouauthor=L.+Commodoreauthor=W.+S.+Huangauthor=Y.+Wangauthor=M.+Thomasauthor=J.+Keatsauthor=Q.+Xuauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=T.+Clacksonauthor=D.+C.+Dalgarnoauthor=X.+Zhu&title=Structural+mechanism+of+the+Pan-BCR-ABL+inhibitor+ponatinib+%28AP24534%29%3A+lessons+for+overcoming+kinase+inhibitor+resistance&doi=10.1111%2Fj.1747-0285.2010.01054.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance</span></div><div class="casAuthors">Zhou Tianjun; Commodore Lois; Huang Wei-Sheng; Wang Yihan; Thomas Mathew; Keats Jeff; Xu Qihong; Rivera Victor M; Shakespeare William C; Clackson Tim; Dalgarno David C; Zhu Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical biology & drug design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia.  However, drug resistance caused by kinase domain mutations has necessitated the development of new mutation-resistant inhibitors, most recently against the T315I gatekeeper residue mutation.  Ponatinib (AP24534) inhibits both native and mutant BCR-ABL, including T315I, acting as a pan-BCR-ABL inhibitor.  Here, we undertook a combined crystallographic and structure-activity relationship analysis on ponatinib to understand this unique profile.  While the ethynyl linker is a key inhibitor functionality that interacts with the gatekeeper, virtually all other components of ponatinib play an essential role in its T315I inhibitory activity.  The extensive network of optimized molecular contacts found in the DFG-out binding mode leads to high potency and renders binding less susceptible to disruption by single point mutations.  The inhibitory mechanism exemplified by ponatinib may have broad relevance to designing inhibitors against other kinases with mutated gatekeeper residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJhwGTLVwV9potVjB3IRIyfW6udTcc2eavUCEIDYdATrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FitVymuw%253D%253D&md5=7f37eef7b6f477d8e356b741497bc69f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2010.01054.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2010.01054.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DStructural%2520mechanism%2520of%2520the%2520Pan-BCR-ABL%2520inhibitor%2520ponatinib%2520%2528AP24534%2529%253A%2520lessons%2520for%2520overcoming%2520kinase%2520inhibitor%2520resistance%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2011%26volume%3D77%26spage%3D1%26epage%3D11%26doi%3D10.1111%2Fj.1747-0285.2010.01054.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikemori-Kawada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jestel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Konig, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, J.</span><span> </span><span class="NLM_article-title">Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1021/ml500394m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500394m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqtb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=89-94&author=K.+Okamotoauthor=M.+Ikemori-Kawadaauthor=A.+Jestelauthor=K.+von+Konigauthor=Y.+Funahashiauthor=T.+Matsushimaauthor=A.+Tsuruokaauthor=A.+Inoueauthor=J.+Matsui&title=Distinct+binding+mode+of+multikinase+inhibitor+lenvatinib+revealed+by+biochemical+characterization&doi=10.1021%2Fml500394m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization</span></div><div class="casAuthors">Okamoto, Kiyoshi; Ikemori-Kawada, Megumi; Jestel, Anja; von Konig, Konstanze; Funahashi, Yasuhiro; Matsushima, Tomohiro; Tsuruoka, Akihiko; Inoue, Atsushi; Matsui, Junji</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-94</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases.  To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction anal. of lenvatinib with VEGFR2 and x-ray anal. of the crystal structure of VEGFR2-lenvatinib complexes.  Kinetic anal. revealed that lenvatinib had a rapid assocn. rate const. and a relatively slow dissocn. rate const. in complex with VEGFR2.  Co-crystal structure anal. demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-"in" conformation.  These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUysiHRGw3P7Vg90H21EOLACvtfcHk0ljx2jJrySrukA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqtb7E&md5=5461832fad0577f2ea93b47521b4bbdc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fml500394m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500394m%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DIkemori-Kawada%26aufirst%3DM.%26aulast%3DJestel%26aufirst%3DA.%26aulast%3Dvon%2BKonig%26aufirst%3DK.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DMatsui%26aufirst%3DJ.%26atitle%3DDistinct%2520binding%2520mode%2520of%2520multikinase%2520inhibitor%2520lenvatinib%2520revealed%2520by%2520biochemical%2520characterization%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D89%26epage%3D94%26doi%3D10.1021%2Fml500394m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M. H.</span><span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0lhfJlNW705eLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+a+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lhfJlNW705eLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520a%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiliotopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajendran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span> </span><span class="NLM_article-title">Structural analysis of the binding of type I, I1/2, and II Inhibitors to Eph tyrosine kinases</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1021/ml500355x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500355x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=79-83&author=J.+Dongauthor=H.+Zhaoauthor=T.+Zhouauthor=D.+Spiliotopoulosauthor=C.+Rajendranauthor=X.+D.+Liauthor=D.+Huangauthor=A.+Caflisch&title=Structural+analysis+of+the+binding+of+type+I%2C+I1%2F2%2C+and+II+Inhibitors+to+Eph+tyrosine+kinases&doi=10.1021%2Fml500355x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fml500355x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500355x%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DSpiliotopoulos%26aufirst%3DD.%26aulast%3DRajendran%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%2BD.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DStructural%2520analysis%2520of%2520the%2520binding%2520of%2520type%2520I%252C%2520I1%252F2%252C%2520and%2520II%2520Inhibitors%2520to%2520Eph%2520tyrosine%2520kinases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D79%26epage%3D83%26doi%3D10.1021%2Fml500355x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Nagashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shumway, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathyanarayanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolinski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilhack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiznerowicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klippel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobkova, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blume-Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northrup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, J. N.</span><span> </span><span class="NLM_article-title">Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">6433</span><span class="NLM_x">–</span> <span class="NLM_lpage">6448</span><span class="refDoi"> DOI: 10.1074/jbc.M110.156463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1074%2Fjbc.M110.156463" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=6433-6448&author=K.+Nagashimaauthor=S.+D.+Shumwayauthor=S.+Sathyanarayananauthor=A.+H.+Chenauthor=B.+Dolinskiauthor=Y.+Xuauthor=H.+Keilhackauthor=T.+Nguyenauthor=M.+Wiznerowiczauthor=L.+Liauthor=B.+A.+Lutterbachauthor=A.+Chiauthor=C.+Paweletzauthor=T.+Allisonauthor=Y.+Yanauthor=S.+K.+Munshiauthor=A.+Klippelauthor=M.+Krausauthor=E.+V.+Bobkovaauthor=S.+Deshmukhauthor=Z.+Xuauthor=U.+Muellerauthor=A.+A.+Szewczakauthor=B.+S.+Panauthor=V.+Richonauthor=R.+Pollockauthor=P.+Blume-Jensenauthor=A.+Northrupauthor=J.+N.+Andersen&title=Genetic+and+pharmacological+inhibition+of+PDK1+in+cancer+cells%3A+characterization+of+a+selective+allosteric+kinase+inhibitor&doi=10.1074%2Fjbc.M110.156463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.156463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.156463%26sid%3Dliteratum%253Aachs%26aulast%3DNagashima%26aufirst%3DK.%26aulast%3DShumway%26aufirst%3DS.%2BD.%26aulast%3DSathyanarayanan%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DA.%2BH.%26aulast%3DDolinski%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DWiznerowicz%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DChi%26aufirst%3DA.%26aulast%3DPaweletz%26aufirst%3DC.%26aulast%3DAllison%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DKlippel%26aufirst%3DA.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DBobkova%26aufirst%3DE.%2BV.%26aulast%3DDeshmukh%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DMueller%26aufirst%3DU.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DPan%26aufirst%3DB.%2BS.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DPollock%26aufirst%3DR.%26aulast%3DBlume-Jensen%26aufirst%3DP.%26aulast%3DNorthrup%26aufirst%3DA.%26aulast%3DAndersen%26aufirst%3DJ.%2BN.%26atitle%3DGenetic%2520and%2520pharmacological%2520inhibition%2520of%2520PDK1%2520in%2520cancer%2520cells%253A%2520characterization%2520of%2520a%2520selective%2520allosteric%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D6433%26epage%3D6448%26doi%3D10.1074%2Fjbc.M110.156463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kim, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canning, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandinova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2145</span><span class="NLM_x">–</span> <span class="NLM_lpage">2150</span><span class="refDoi"> DOI: 10.1021/cb400430t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400430t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFyhsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2145-2150&author=H.+G.+Kimauthor=L.+Tanauthor=E.+L.+Weisbergauthor=F.+Liuauthor=P.+Canningauthor=H.+G.+Choiauthor=S.+A.+Ezellauthor=H.+Wuauthor=Z.+Zhaoauthor=J.+Wangauthor=A.+Mandinovaauthor=J.+D.+Griffinauthor=A.+N.+Bullockauthor=Q.+Liuauthor=S.+W.+Leeauthor=N.+S.+Gray&title=Discovery+of+a+potent+and+selective+DDR1+receptor+tyrosine+kinase+inhibitor&doi=10.1021%2Fcb400430t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Kim, Hyung-Gu; Tan, Li; Weisberg, Ellen L.; Liu, Feiyang; Canning, Peter; Choi, Hwan Geun; Ezell, Scott A.; Wu, Hong; Zhao, Zheng; Wang, Jinhua; Mandinova, Anna; Griffin, James D.; Bullock, Alex N.; Liu, Qingsong; Lee, Sam W.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2145-2150</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The DDR1 receptor tyrosine kinase is activated by matrix collagens and has been implicated in numerous cellular functions such as proliferation, differentiation, adhesion, migration, and invasion.  Here we report the discovery of a potent and selective DDR1 inhibitor, DDR1-IN-1, and present the 2.2 Å DDR1 co-crystal structure.  DDR1-IN-1 binds to DDR1 in the DFG-out' conformation and inhibits DDR1 autophosphorylation in cells at submicromolar concns. with good selectivity as assessed against a panel of 451 kinases measured using the KinomeScan technol.  We identified a mutation in the hinge region of DDR1, G707A, that confers >20-fold resistance to the ability of DDR1-IN-1 to inhibit DDR1 autophosphorylation and can be used to establish what pharmacol. is DDR1-dependent.  A combinatorial screen of DDR1-IN-1 with a library of annotated kinase inhibitors revealed that inhibitors of PI3K and mTOR such as GSK2126458 potentiate the antiproliferative activity of DDR1-IN-1 in colorectal cancer cell lines.  DDR1-IN-1 provides a useful pharmacol. probe for DDR1-dependent signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAGEEijNuQNLVg90H21EOLACvtfcHk0ljpLse-pU8ykg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFyhsbbE&md5=ed0921658bbf54c35a2246d63968adb3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fcb400430t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400430t%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BG.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DEzell%26aufirst%3DS.%2BA.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMandinova%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520DDR1%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D2145%26epage%3D2150%26doi%3D10.1021%2Fcb400430t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.18632/oncotarget.10037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.18632%2Foncotarget.10037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+Liuauthor=B.+Wangauthor=Q.+Wangauthor=Z.+Qiauthor=C.+Chenauthor=L.-L.+Kongauthor=J.-Y.+Chenauthor=X.+Liuauthor=A.+Wangauthor=C.+Huauthor=W.+Wangauthor=H.+Wangauthor=F.+Wuauthor=Y.+Ruanauthor=S.+Qiauthor=J.+Liuauthor=F.+Zouauthor=Z.+Huauthor=W.+Wangauthor=L.+Wangauthor=S.+Zhangauthor=C.-H.+Yunauthor=Z.+Zhaiauthor=J.+Liuauthor=Q.+Liu&title=Discovery+and+characterization+of+a+novel+potent+type+II+native+and+mutant+BCR-ABL+inhibitor+%28CHMFL-074%29+for+Chronic+Myeloid+Leukemia+%28CML%29&doi=10.18632%2Foncotarget.10037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10037%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DL.-L.%26aulast%3DChen%26aufirst%3DJ.-Y.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DRuan%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DZhai%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520novel%2520potent%2520type%2520II%2520native%2520and%2520mutant%2520BCR-ABL%2520inhibitor%2520%2528CHMFL-074%2529%2520for%2520Chronic%2520Myeloid%2520Leukemia%2520%2528CML%2529%26jtitle%3DOncotarget%26date%3D2016%26doi%3D10.18632%2Foncotarget.10037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lhgnLdMgJaSYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Williams, L. T.</span><span> </span><span class="NLM_article-title">Signal transduction by the platelet-derived growth factor receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">243</span><span class="NLM_x">, </span> <span class="NLM_fpage">1564</span><span class="NLM_x">–</span> <span class="NLM_lpage">1570</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1989&pages=1564-1570&author=L.+T.+Williams&title=Signal+transduction+by+the+platelet-derived+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DL.%2BT.%26atitle%3DSignal%2520transduction%2520by%2520the%2520platelet-derived%2520growth%2520factor%2520receptor%26jtitle%3DScience%26date%3D1989%26volume%3D243%26spage%3D1564%26epage%3D1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Torres, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bill, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghadimi, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolshakov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belousov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lev, D.</span><span> </span><span class="NLM_article-title">Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3943</span><span class="NLM_x">–</span> <span class="NLM_lpage">3955</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1158%2F1078-0432.CCR-11-0193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=21540237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=3943-3955&author=K.+E.+Torresauthor=Q.+S.+Zhuauthor=K.+Billauthor=G.+Lopezauthor=M.+P.+Ghadimiauthor=X.+Xieauthor=E.+D.+Youngauthor=J.+Liuauthor=T.+Nguyenauthor=S.+Bolshakovauthor=R.+Belousovauthor=S.+Wangauthor=G.+Lahatauthor=J.+Liuauthor=B.+Hernandezauthor=A.+J.+Lazarauthor=D.+Lev&title=Activated+MET+is+a+molecular+prognosticator+and+potential+therapeutic+target+for+malignant+peripheral+nerve+sheath+tumors&doi=10.1158%2F1078-0432.CCR-11-0193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors</span></div><div class="casAuthors">Torres, Keila E.; Zhu, Quan-Sheng; Bill, Katelynn; Lopez, Gonzalo; Ghadimi, Markus P.; Xie, Xian-Biao; Young, Eric D.; Liu, Jue-Hui; Nguyen, Theresa; Bolshakov, Svetlana; Belousov, Roman; Wang, Sui-Zhau; Lahat, Guy; Liu, Jun; Hernandez, Belinda; Lazar, Alexander J.; Lev, Dina</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3943-3955</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MET signaling has been suggested a potential role in malignant peripheral nerve sheath tumors (MPNST).  Here, MET function and blockade were preclinically assessed.  Exptl. Design: Expression levels of MET, its ligand hepatocyte growth factor (HGF), and phosphorylated MET (pMET) were examd. in a clin. annotated MPNST tissue microarray (TMA) incorporating univariable and multivariable statistical analyses.  Human MPNST cells were studied in vitro and in vivo; Western blot (WB) and ELISA were used to evaluate MET and HGF expression, activation, and downstream signaling.  Cell culture assays tested the impact of HGF-induced MET activation and anti-MET-specific siRNA inhibition on cell proliferation, migration, and invasion; in vivo gel-foam assays were used to evaluate angiogenesis.  Cells stably transduced with anti-MET short hairpin RNA (shRNA) constructs were tested for growth and metastasis in severe combined immunodeficient (SCID) mice.  The effect of the tyrosine kinase inhibitor XL184 (Exelixis) targeting MET/VEGFR2 (vascular endothelial growth factor receptor 2) on local and metastatic MPNST growth was examd. in vivo.  All three markers were expressed in MPNST human samples; pMET expression was an independent prognosticator of poor patient outcome.  Human MPNST cell lines expressed MET, HGF, and pMET.  MET activation increased MPNST cell motility, invasion, angiogenesis, and induced matrix metalloproteinase-2 (MMP2) and VEGF expression; MET knockdown had inverse effects in vitro and markedly decreased local and metastatic growth in vivo.  XL184 abrogated human MPNST xenograft growth and metastasis in SCID mice.  Informative prognosticators and novel therapies are crucially needed to improve MPNST management and outcomes.  We show an important role for MET in MPNST, supporting continued investigation of novel anti-MET therapies in this clin. context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Nx2rtKdYt7Vg90H21EOLACvtfcHk0lhgnLdMgJaSYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKgsbg%253D&md5=494fe0a3b10bf230db323396a5f57211</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0193%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DK.%2BE.%26aulast%3DZhu%26aufirst%3DQ.%2BS.%26aulast%3DBill%26aufirst%3DK.%26aulast%3DLopez%26aufirst%3DG.%26aulast%3DGhadimi%26aufirst%3DM.%2BP.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DYoung%26aufirst%3DE.%2BD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DBolshakov%26aufirst%3DS.%26aulast%3DBelousov%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLahat%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DLev%26aufirst%3DD.%26atitle%3DActivated%2520MET%2520is%2520a%2520molecular%2520prognosticator%2520and%2520potential%2520therapeutic%2520target%2520for%2520malignant%2520peripheral%2520nerve%2520sheath%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D3943%26epage%3D3955%26doi%3D10.1158%2F1078-0432.CCR-11-0193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Valiathan, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitinger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleer, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, R.</span><span> </span><span class="NLM_article-title">Discoidin domain receptor tyrosine kinases: new players in cancer progression</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">321</span><span class="refDoi"> DOI: 10.1007/s10555-012-9346-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1007%2Fs10555-012-9346-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=22366781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=295-321&author=R.+R.+Valiathanauthor=M.+Marcoauthor=B.+Leitingerauthor=C.+G.+Kleerauthor=R.+Fridman&title=Discoidin+domain+receptor+tyrosine+kinases%3A+new+players+in+cancer+progression&doi=10.1007%2Fs10555-012-9346-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discoidin domain receptor tyrosine kinases: new players in cancer progression</span></div><div class="casAuthors">Valiathan, Rajeshwari R.; Marco, Marta; Leitinger, Birgit; Kleer, Celina G.; Fridman, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">295-321</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Almost all human cancers display dysregulated expression and/or function of one or more receptor tyrosine kinases (RTKs).  The strong causative assocn. between altered RTK function and cancer progression has been translated into novel therapeutic strategies that target these cell surface receptors in cancer.  Yet, the full spectrum of RTKs that may alter the oncogenic process is not completely understood.  Accumulating evidence suggests that a unique set of RTKs known as the discoidin domain receptors (DDRs) play a key role in cancer progression by regulating the interactions of tumor cells with their surrounding collagen matrix.  The DDRs are the only RTKs that specifically bind to and are activated by collagen.  DDRs control cell and tissue homeostasis by acting as collagen sensors, transducing signals that regulate cell polarity, tissue morphogenesis, and cell differentiation.  In cancer, DDRs are hijacked by tumor cells to disrupt normal cell-matrix communication and initiate pro-migratory and pro-invasive programs.  Importantly, several cancer types exhibit DDR mutations, which are thought to alter receptor function and contribute to cancer progression.  Other evidence suggests that the actions of DDRs in cancer are complex, either promoting or suppressing tumor cell behavior in a DDR type/isoform specific- and context-dependent manner.  Thus, there is still a considerable gap in our knowledge of DDR actions in cancer tissues.  This review summarizes and discusses the current knowledge on DDR expression and function in cancer.  It is hoped that this effort will encourage more research into these poorly understood but unique RTKs, which have the potential of becoming novel therapeutic targets in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6IvVtcaWbw7Vg90H21EOLACvtfcHk0lhGaJRy6o5Jbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFajs7c%253D&md5=da63c7783212d348b80aeaef7d90094c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs10555-012-9346-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-012-9346-z%26sid%3Dliteratum%253Aachs%26aulast%3DValiathan%26aufirst%3DR.%2BR.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DLeitinger%26aufirst%3DB.%26aulast%3DKleer%26aufirst%3DC.%2BG.%26aulast%3DFridman%26aufirst%3DR.%26atitle%3DDiscoidin%2520domain%2520receptor%2520tyrosine%2520kinases%253A%2520new%2520players%2520in%2520cancer%2520progression%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2012%26volume%3D31%26spage%3D295%26epage%3D321%26doi%3D10.1007%2Fs10555-012-9346-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Pollard, J. W.</span><span> </span><span class="NLM_article-title">Trophic macrophages in development and disease</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nri2528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1038%2Fnri2528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=19282852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=259-270&author=J.+W.+Pollard&title=Trophic+macrophages+in+development+and+disease&doi=10.1038%2Fnri2528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Trophic macrophages in development and disease</span></div><div class="casAuthors">Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Specialized phagocytes are found in the most primitive multicellular organisms.  Their roles in homeostasis and in distinguishing self from non-self have evolved with the complexity of organisms and their immune systems.  Equally important, but often overlooked, are the roles of macrophages in tissue development.  As discussed in this Review, these include functions in branching morphogenesis, neuronal patterning, angiogenesis, bone morphogenesis and the generation of adipose tissue.  In each case, macrophage depletion impairs the formation of the tissue and compromises its function.  I argue that in several diseases, the unrestrained acquisition of these developmental macrophage functions exacerbates pathol.  For example, macrophages enhance tumor progression and metastasis by affecting tumor-cell migration and invasion, as well as angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR03M07hzbU7Vg90H21EOLACvtfcHk0lhGaJRy6o5Jbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D&md5=d29685d4cbb8d8bdd296f8b8ff869d36</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnri2528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2528%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTrophic%2520macrophages%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D259%26epage%3D270%26doi%3D10.1038%2Fnri2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rossato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiesko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedani, A.</span><span> </span><span class="NLM_article-title">Probing small-molecule binding to cytochrome P450 2D6 and 2C9: an in silico protocol for generating toxicity alerts</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2088</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span><span class="refDoi"> DOI: 10.1002/cmdc.201000358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1002%2Fcmdc.201000358" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=2088-2101&author=G.+Rossatoauthor=B.+Ernstauthor=M.+Smieskoauthor=M.+Spreaficoauthor=A.+Vedani&title=Probing+small-molecule+binding+to+cytochrome+P450+2D6+and+2C9%3A+an+in+silico+protocol+for+generating+toxicity+alerts&doi=10.1002%2Fcmdc.201000358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000358%26sid%3Dliteratum%253Aachs%26aulast%3DRossato%26aufirst%3DG.%26aulast%3DErnst%26aufirst%3DB.%26aulast%3DSmiesko%26aufirst%3DM.%26aulast%3DSpreafico%26aufirst%3DM.%26aulast%3DVedani%26aufirst%3DA.%26atitle%3DProbing%2520small-molecule%2520binding%2520to%2520cytochrome%2520P450%25202D6%2520and%25202C9%253A%2520an%2520in%2520silico%2520protocol%2520for%2520generating%2520toxicity%2520alerts%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D2088%26epage%3D2101%26doi%3D10.1002%2Fcmdc.201000358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Word, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span> </span><span class="NLM_article-title">Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation 1</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">1735</span><span class="NLM_x">–</span> <span class="NLM_lpage">1747</span><span class="refDoi"> DOI: 10.1006/jmbi.1998.2401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1006%2Fjmbi.1998.2401" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=1735-1747&author=J.+M.+Wordauthor=S.+C.+Lovellauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=Asparagine+and+glutamine%3A+using+hydrogen+atom+contacts+in+the+choice+of+side-chain+amide+orientation+1&doi=10.1006%2Fjmbi.1998.2401"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1998.2401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1998.2401%26sid%3Dliteratum%253Aachs%26aulast%3DWord%26aufirst%3DJ.%2BM.%26aulast%3DLovell%26aufirst%3DS.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DAsparagine%2520and%2520glutamine%253A%2520using%2520hydrogen%2520atom%2520contacts%2520in%2520the%2520choice%2520of%2520side-chain%2520amide%2520orientation%25201%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D285%26spage%3D1735%26epage%3D1747%26doi%3D10.1006%2Fjmbi.1998.2401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Dobler, M.</span>BioX, a Versatile Molecular-Modeling Software; <span class="NLM_publisher-name">Biographics Laboratory 3R</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.biograf.ch/index.php?id=software" class="extLink">http://www.biograf.ch/index.php?id=software</a> (updated Nov 8, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Dobler&title=BioX%2C+a+Versatile+Molecular-Modeling+Software"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDobler%26aufirst%3DM.%26jtitle%3DBioX%252C%2520a%2520Versatile%2520Molecular-Modeling%2520Software%26pub%3DBiographics%2520Laboratory%25203R%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Vedani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huhta, D. W.</span><span> </span><span class="NLM_article-title">A new force field for modeling metalloproteins</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">4759</span><span class="NLM_x">–</span> <span class="NLM_lpage">4767</span><span class="refDoi"> DOI: 10.1021/ja00168a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00168a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADyaK3cXktVaqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=1990&pages=4759-4767&author=A.+Vedaniauthor=D.+W.+Huhta&title=A+new+force+field+for+modeling+metalloproteins&doi=10.1021%2Fja00168a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A new force field for modeling metalloproteins</span></div><div class="casAuthors">Vedani, Angelo; Huhta, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4759-67</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">A force field for the simulation of metalloproteins features a new potential function for modeling metal-ligand interactions.  This function includes s variables the metal-ligand sepns., the symmetry at the metal center, directionality of the metal-ligand bonds, ligand-metal charge transfer, and (for transition-metal ions) ligand-field stabilization.  The function was developed based on the anal. of accurate small-mol. crystal structures retrieved from the Cambridge Structural Database and incorporated into the mol. mechanics program Yeti which also includes directional terms for H-bonds and salt linkages in its force field energy expression.  The program then was used to model details of metal-coordination, H-bond network formation and protein-solvent interactions in native, complexed, and Co(II)-substituted human carbonic anhydrase I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMppUxyYGE4rVg90H21EOLACvtfcHk0lg9Nz5-f6Eeuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktVaqsLs%253D&md5=107e319b852d73f13359ea3f40f99f14</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja00168a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00168a021%26sid%3Dliteratum%253Aachs%26aulast%3DVedani%26aufirst%3DA.%26aulast%3DHuhta%26aufirst%3DD.%2BW.%26atitle%3DA%2520new%2520force%2520field%2520for%2520modeling%2520metalloproteins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1990%26volume%3D112%26spage%3D4759%26epage%3D4767%26doi%3D10.1021%2Fja00168a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Lu</span>, <span class="hlFld-ContribAuthor ">Jiangyan  Cao</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Xixiang  Li</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Huamin  Liang</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Ge</span>, <span class="hlFld-ContribAuthor ">Yang  Shen</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Ruixiang  Xia</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2021,</strong> <em>897 </em>, 173944. <a href="https://doi.org/10.1016/j.ejphar.2021.173944" title="DOI URL">https://doi.org/10.1016/j.ejphar.2021.173944</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2021.173944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2021.173944%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DDiscovery%252Bof%252Ba%252Bhighly%252Bpotent%252Bkinase%252Binhibitor%252Bcapable%252Bof%252Bovercoming%252Bmultiple%252Bimatinib-resistant%252BABL%252Bmutants%252Bfor%252Bchronic%252Bmyeloid%252Bleukemia%252B%252528CML%252529%26aulast%3DLu%26aufirst%3DTingting%26date%3D2021%26volume%3D897%26spage%3D173944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dejuan  Sun</span>, <span class="hlFld-ContribAuthor ">Yuqian  Zhao</span>, <span class="hlFld-ContribAuthor ">Shouyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Lan  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-target kinase drug design: Current strategies and future directions in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 112025. <a href="https://doi.org/10.1016/j.ejmech.2019.112025" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.112025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.112025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.112025%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-target%252Bkinase%252Bdrug%252Bdesign%25253A%252BCurrent%252Bstrategies%252Band%252Bfuture%252Bdirections%252Bin%252Bcancer%252Btherapy%26aulast%3DSun%26aufirst%3DDejuan%26date%3D2020%26volume%3D188%26spage%3D112025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Xixiang  Li</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Tao  Huang</span>, <span class="hlFld-ContribAuthor ">Ming  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Ge</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Ruixiang  Xia</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML). </span><span class="cited-content_cbyCitation_journal-name">Cancer Biology & Therapy</span><span> <strong>2019,</strong> <em>20 </em>
                                    (6)
                                     , 877-885. <a href="https://doi.org/10.1080/15384047.2019.1579958" title="DOI URL">https://doi.org/10.1080/15384047.2019.1579958</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15384047.2019.1579958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15384047.2019.1579958%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Biology%2520%2526%2520Therapy%26atitle%3DDiscovery%252Band%252Bcharacterization%252Bof%252Ba%252Bnovel%252Bhighly%252Bpotent%252Band%252Bselective%252Btype%252BII%252Bnative%252Band%252Bdrug-resistant%252BV299L%252Bmutant%252BBCR-ABL%252Binhibitor%252B%252528CHMFL-ABL-039%252529%252Bfor%252BChronic%252BMyeloid%252BLeukemia%252B%252528CML%252529%26aulast%3DWu%26aufirst%3DJiaxin%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D6%26spage%3D877%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Lu</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Feiyang  Liu</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Tang</span>, <span class="hlFld-ContribAuthor ">Hezhong  Yan</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Bai</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>447 </em>, 105-114. <a href="https://doi.org/10.1016/j.canlet.2019.01.024" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.01.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.01.024%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DRepurposing%252Bcabozantinib%252Bto%252BGISTs%25253A%252BOvercoming%252Bmultiple%252Bimatinib-resistant%252BcKIT%252Bmutations%252Bincluding%252Bgatekeeper%252Band%252Bactivation%252Bloop%252Bmutants%252Bin%252BGISTs%252Bpreclinical%252Bmodels%26aulast%3DLu%26aufirst%3DTingting%26date%3D2019%26volume%3D447%26spage%3D105%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative type II inhibitors with nitrogen-mediated hinge binding (<b>1</b>–<b>7</b>) and distinct oxygen-mediated hinge binding (<b>8</b>–<b>10</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of discovery of compound <b>34</b> with distinct hinge binding. (A) X-ray cocrystal structure of compound <b>12</b> with ABL kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HU9">5HU9</a>). (B) Structure–activity relationship (SAR) investigation route leading to compound <b>34</b> (CHMFL-ABL/KIT-155).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>11</b> and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, overnight; (b) 4 N HCl in EtOAc, rt, overnight; (c) nicotinic acid, HATU, DIPEA, DMF, rt, 2 h; (d) H<sub>2</sub>, Pd/C, EtOAc, rt, 6 h; (e) R3-COOH, HATU, DIPEA, DMF, rt, 2 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>13</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) for <b>41a</b>,<b>e</b>,<b>f</b>, <i>tert</i>-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate; for <b>41b</b>, <i>tert</i>-butyl 3-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate; for <b>41c</b>, <i>tert</i>-butyl 3-(((methylsulfonyl)oxy)methyl) azetidine-1-carboxylate; for <b>41d</b>, <i>tert</i>-butyl (2-bromoethyl)carbamate, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, overnight; (b) H<sub>2</sub>, Pd/C, EtOAc, rt, 6 h; (c) 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) benzoic acid, HATU, DIPEA, DMF, rt, 2 h; (d) 4 N HCl in EtOAc, rt, overnight; (e) for <b>13</b>–<b>36</b>, carboxylic acid derivatives, HATU, DIPEA, DMF, rt, 2 h; for <b>37</b>, benzenesulfonyl chloride, DIPEA, DMF, rt, 2 h; for <b>38</b>, 4-chloro-6,7-dimethoxyquinazoline; and for <b>39</b>, 2-chloropyrimidine, DIPEA, <i>n</i>-butyl alcohol, reflux, overnight.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Activity and selectivity characterization of compound <b>34</b>. (A) Biochemical assay characterization of the inhibitory activities of <b>1</b>, <b>23</b>, <b>24</b>, and <b>32</b>–<b>34</b> against primary targets ABL1 and KIT kinases. (B) KINOMEscan profiling of <b>34</b> at a concentration of 1 μM against 468 kinases and its biochemical inhibitory activities to the selected kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding modes of compound <b>34</b> in complex with ABL1 and c-KIT kinases. (A) Docking of <b>34</b> in complex with ABL1 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HU9">5HU9</a>). (B) Docking of <b>34</b> in complex with c-KIT kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>1</b> and <b>34</b> on the signaling transduction pathways. (A) Effects of <b>1</b> and <b>34</b> on the BCR-ABL mediated signaling pathways in the BCR-ABL dependent CML cell lines (K562, KU812, and MEG-01). (B) Effects of <b>1</b> and <b>34</b> on the c-KIT mediated signaling pathways in the c-KIT dependent (GIST-T1 and GIST-882) and c-KIT independent (GIST-48B) cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of compounds <b>1</b> and <b>34</b> on induction of cell cycle progression in (A) K562, KU812, and MEG-01 CML cells and (B) GIST-T1, GIST-882, and GIST-48B GISTs cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of compounds <b>1</b> and <b>34</b> on apoptosis in (A) K562, KU812, and MEG-01 CML cells and (B) GIST-T1, GIST882, and GIST-48B GISTs cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>34</b>’s antitumor efficacy in K562 xenograft mouse model. Female nu/nu mice bearing established K562 tumor xenografts were treated with <b>34</b> at 25.0, 50.0, and 100 mg/kg/d dosage, 100 mg/kg/d imatinib, or vehicle. Daily oral administration was initiated when K562 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained four or five animals. Data, mean ± SEM, (A) body weight, and (B) tumor size measurements from K562 xenograft mice after <b>34</b> and imatinib administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 0, 25.0, 50.0, or 100 mg/kg/d <b>34</b> and 100 mg/kg/d imatinib treatment. (D) Comparison of the final tumor weight in each group after 28-day treatment period of <b>34</b> and imatinib. Numbers in columns indicate the mean tumor weight in each group. *<i>p</i> < 0.05. (E) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues with <b>34</b> treatment groups in comparison with the vehicle and imatinib treatment group. Note the specific nuclear staining of cells with morphology consistent with proliferation and apoptosis (E, blue arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/medium/jm-2016-01290s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>34</b>’s antitumor efficacy in GIST-T1 xenograft mouse model. Female nu/nu mice bearing established GIST-T1 tumor xenografts were treated with <b>34</b> at 25.0, 50.0, and 100 mg/kg/d dosage, or vehicle. Daily oral administration was initiated when GIST-T1 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained five animals. Data, mean ± SEM, (A) body weight, and (B) tumor size measurements from GIST-T1 xenograft mice after <b>34</b> administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 25.0, 50.0, or 100 mg/kg/d <b>34</b> or vehicle treatment. (D) Comparison of the final tumor weight in each group after 21-day treatment period of <b>34</b>. Numbers in columns indicate the mean tumor weight in each group. ns, <i>p</i> > 0.05, *<i>p</i> < 0.05, **<i>p</i> < 0.01. (E) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues with <b>34</b> treatment groups in comparison with the vehicle group. Note the specific nuclear staining of cells with morphology consistent with proliferation and apoptosis (E, blue arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01290/20170106/images/large/jm-2016-01290s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01290&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 22 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span><span class="refDoi"> DOI: 10.1126/science.289.5486.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+abelson+tyrosine+kinase&doi=10.1126%2Fscience.289.5486.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lit8uTzYf5zlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942%26doi%3D10.1126%2Fscience.289.5486.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulfert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">13286</span><span class="NLM_x">–</span> <span class="NLM_lpage">13296</span><span class="refDoi"> DOI: 10.1021/ja902010p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja902010p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1ensrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=13286-13296&author=J.+R.+Simardauthor=M.+Getlikauthor=C.+Grutterauthor=V.+Pawarauthor=S.+Wulfertauthor=M.+Rabillerauthor=D.+Rauh&title=Development+of+a+fluorescent-tagged+kinase+assay+system+for+the+detection+and+characterization+of+allosteric+kinase+inhibitors&doi=10.1021%2Fja902010p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors</span></div><div class="casAuthors">Simard, Jeffrey R.; Getlik, Matthaus; Grutter, Christian; Pawar, Vijaykumar; Wulfert, Sabine; Rabiller, Matthias; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">13286-13296</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinase disregulation disrupts the intricate network of intracellular signaling pathways and contributes to the onset of diseases such as cancer.  Although several kinase inhibitors are on the market, inhibitor selectivity and drug resistance mutations persist as fundamental challenges in the development of effective long-term treatments.  Chem. entities binding to less conserved allosteric sites would be expected to offer new opportunities for scaffold development.  Because no high-throughput method was previously available, a fluorescence-based kinase binding assay for identifying and characterizing ligands which stabilize the inactive kinase conformation was developed.  Here, a description of the development and validation of this assay using the serine/threonine kinase p38α is presented.  The covalent attachment of fluorophores to the activation loop of the kinase allowed to detect the conformational changes and measure the Kd, kon, and koff assocd. with the binding and dissocn. of ligands to the allosteric pocket.  The SAR of a synthesized focused library of pyrazolourea derivs., a scaffold known to bind with high affinity to the allosteric pocket of p38α, is also reported.  Addnl., the protein X-ray crystallog. was used together with this assay to examine the binding and dissocn. kinetics to characterize potent quinazoline- and quinoline-based type II inhibitors, which also utilize this binding pocket in p38α.  Last, the b-Raf inhibitor sorafenib was identified as a potent low nanomolar inhibitor of p38α and the protein X-ray crystallog. was used to confirm its unique binding mode to the inactive kinase conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVNeYPzX2CHbVg90H21EOLACvtfcHk0ljgyciAknnJeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1ensrk%253D&md5=f56e476572c7cdfb3411eb95b9759fca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fja902010p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja902010p%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DWulfert%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520a%2520fluorescent-tagged%2520kinase%2520assay%2520system%2520for%2520the%2520detection%2520and%2520characterization%2520of%2520allosteric%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D13286%26epage%3D13296%26doi%3D10.1021%2Fja902010p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.ccr.2005.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl&doi=10.1016%2Fj.ccr.2005.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0ljgyciAknnJeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141%26doi%3D10.1016%2Fj.ccr.2005.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zopf, D.</span><span> </span><span class="NLM_article-title">Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1002/ijc.25864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1002%2Fijc.25864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=21170960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=245-255&author=S.+M.+Wilhelmauthor=J.+Dumasauthor=L.+Adnaneauthor=M.+Lynchauthor=C.+A.+Carterauthor=G.+Schutzauthor=K.+H.+Thierauchauthor=D.+Zopf&title=Regorafenib+%28BAY+73%E2%80%934506%29%3A+a+new+oral+multikinase+inhibitor+of+angiogenic%2C+stromal+and+oncogenic+receptor+tyrosine+kinases+with+potent+preclinical+antitumor+activity&doi=10.1002%2Fijc.25864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span></div><div class="casAuthors">Wilhelm, Scott M.; Dumas, Jacques; Adnane, Lila; Lynch, Mark; Carter, Christopher A.; Schuetz, Gunnar; Thierauch, Karl-Heinz; Zopf, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-255</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Angiogenesis, a crit. driver of tumor development, is controlled by interconnected signaling pathways.  Vascular endothelial growth factor receptor (VEGFR) 2 and tyrosine kinase with Ig and epidermal growth factor homol. domain 2 play crucial roles in the biol. of normal and tumor vasculature.  Regorafenib (BAY 73-4506), a novel oral multikinase inhibitor, potently inhibits these endothelial cell kinases in biochem. and cellular kinase phosphorylation assays.  Furthermore, regorafenib inhibits addnl. angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF.  The antiangiogenic effect of regorafenib was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging.  Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts.  In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 h after the last dosing and correlated with tumor growth inhibition (TGI).  A significant redn. in tumor microvessel area was obsd. in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg.  Regorafenib exhibited potent dose-dependent TGI in various preclin. human xenograft models in mice, with tumor shrinkages obsd. in breast MDA-MB-231 and renal 786-O carcinoma models.  Pharmacodynamic analyses of the breast model revealed strong redn. in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2.  These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQpQXfCq04rVg90H21EOLACvtfcHk0ljEYgaj3L8C9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D&md5=13eee29ef1f1f03fd1ed311ea613f566</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fijc.25864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25864%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DSchutz%26aufirst%3DG.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26aulast%3DZopf%26aufirst%3DD.%26atitle%3DRegorafenib%2520%2528BAY%252073%25E2%2580%25934506%2529%253A%2520a%2520new%2520oral%2520multikinase%2520inhibitor%2520of%2520angiogenic%252C%2520stromal%2520and%2520oncogenic%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520preclinical%2520antitumor%2520activity%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D245%26epage%3D255%26doi%3D10.1002%2Fijc.25864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">You, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennino, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcón, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashizume, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aftab, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcdonald, D. M.</span><span> </span><span class="NLM_article-title">VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4758</span><span class="NLM_x">–</span> <span class="NLM_lpage">4768</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1158%2F0008-5472.CAN-10-2527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4758-4768&author=W.+K.+Youauthor=B.+Senninoauthor=C.+W.+Williamsonauthor=B.+Falc%C3%B3nauthor=H.+Hashizumeauthor=L.+C.+Yaoauthor=D.+T.+Aftabauthor=D.+M.+Mcdonald&title=VEGF+and+c-Met+blockade+amplify+angiogenesis+inhibition+in+pancreatic+islet+cancer&doi=10.1158%2F0008-5472.CAN-10-2527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2527%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DW.%2BK.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DWilliamson%26aufirst%3DC.%2BW.%26aulast%3DFalc%25C3%25B3n%26aufirst%3DB.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DL.%2BC.%26aulast%3DAftab%26aufirst%3DD.%2BT.%26aulast%3DMcdonald%26aufirst%3DD.%2BM.%26atitle%3DVEGF%2520and%2520c-Met%2520blockade%2520amplify%2520angiogenesis%2520inhibition%2520in%2520pancreatic%2520islet%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4758%26epage%3D4768%26doi%3D10.1158%2F0008-5472.CAN-10-2527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2010.01054.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1111%2Fj.1747-0285.2010.01054.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=21118377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FitVymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2011&pages=1-11&author=T.+Zhouauthor=L.+Commodoreauthor=W.+S.+Huangauthor=Y.+Wangauthor=M.+Thomasauthor=J.+Keatsauthor=Q.+Xuauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=T.+Clacksonauthor=D.+C.+Dalgarnoauthor=X.+Zhu&title=Structural+mechanism+of+the+Pan-BCR-ABL+inhibitor+ponatinib+%28AP24534%29%3A+lessons+for+overcoming+kinase+inhibitor+resistance&doi=10.1111%2Fj.1747-0285.2010.01054.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance</span></div><div class="casAuthors">Zhou Tianjun; Commodore Lois; Huang Wei-Sheng; Wang Yihan; Thomas Mathew; Keats Jeff; Xu Qihong; Rivera Victor M; Shakespeare William C; Clackson Tim; Dalgarno David C; Zhu Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical biology & drug design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia.  However, drug resistance caused by kinase domain mutations has necessitated the development of new mutation-resistant inhibitors, most recently against the T315I gatekeeper residue mutation.  Ponatinib (AP24534) inhibits both native and mutant BCR-ABL, including T315I, acting as a pan-BCR-ABL inhibitor.  Here, we undertook a combined crystallographic and structure-activity relationship analysis on ponatinib to understand this unique profile.  While the ethynyl linker is a key inhibitor functionality that interacts with the gatekeeper, virtually all other components of ponatinib play an essential role in its T315I inhibitory activity.  The extensive network of optimized molecular contacts found in the DFG-out binding mode leads to high potency and renders binding less susceptible to disruption by single point mutations.  The inhibitory mechanism exemplified by ponatinib may have broad relevance to designing inhibitors against other kinases with mutated gatekeeper residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJhwGTLVwV9potVjB3IRIyfW6udTcc2eayCnm8GOvoO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FitVymuw%253D%253D&md5=7f37eef7b6f477d8e356b741497bc69f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2010.01054.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2010.01054.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DStructural%2520mechanism%2520of%2520the%2520Pan-BCR-ABL%2520inhibitor%2520ponatinib%2520%2528AP24534%2529%253A%2520lessons%2520for%2520overcoming%2520kinase%2520inhibitor%2520resistance%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2011%26volume%3D77%26spage%3D1%26epage%3D11%26doi%3D10.1111%2Fj.1747-0285.2010.01054.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikemori-Kawada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jestel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Konig, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, J.</span><span> </span><span class="NLM_article-title">Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1021/ml500394m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500394m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqtb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=89-94&author=K.+Okamotoauthor=M.+Ikemori-Kawadaauthor=A.+Jestelauthor=K.+von+Konigauthor=Y.+Funahashiauthor=T.+Matsushimaauthor=A.+Tsuruokaauthor=A.+Inoueauthor=J.+Matsui&title=Distinct+binding+mode+of+multikinase+inhibitor+lenvatinib+revealed+by+biochemical+characterization&doi=10.1021%2Fml500394m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization</span></div><div class="casAuthors">Okamoto, Kiyoshi; Ikemori-Kawada, Megumi; Jestel, Anja; von Konig, Konstanze; Funahashi, Yasuhiro; Matsushima, Tomohiro; Tsuruoka, Akihiko; Inoue, Atsushi; Matsui, Junji</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-94</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases.  To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction anal. of lenvatinib with VEGFR2 and x-ray anal. of the crystal structure of VEGFR2-lenvatinib complexes.  Kinetic anal. revealed that lenvatinib had a rapid assocn. rate const. and a relatively slow dissocn. rate const. in complex with VEGFR2.  Co-crystal structure anal. demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-"in" conformation.  These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUysiHRGw3P7Vg90H21EOLACvtfcHk0ljQbYznH6qiKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqtb7E&md5=5461832fad0577f2ea93b47521b4bbdc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fml500394m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500394m%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DIkemori-Kawada%26aufirst%3DM.%26aulast%3DJestel%26aufirst%3DA.%26aulast%3Dvon%2BKonig%26aufirst%3DK.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DMatsui%26aufirst%3DJ.%26atitle%3DDistinct%2520binding%2520mode%2520of%2520multikinase%2520inhibitor%2520lenvatinib%2520revealed%2520by%2520biochemical%2520characterization%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D89%26epage%3D94%26doi%3D10.1021%2Fml500394m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M. H.</span><span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0ljQbYznH6qiKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+a+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lhAdJrmoEOASg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520a%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiliotopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajendran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span> </span><span class="NLM_article-title">Structural analysis of the binding of type I, I1/2, and II Inhibitors to Eph tyrosine kinases</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1021/ml500355x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500355x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=79-83&author=J.+Dongauthor=H.+Zhaoauthor=T.+Zhouauthor=D.+Spiliotopoulosauthor=C.+Rajendranauthor=X.+D.+Liauthor=D.+Huangauthor=A.+Caflisch&title=Structural+analysis+of+the+binding+of+type+I%2C+I1%2F2%2C+and+II+Inhibitors+to+Eph+tyrosine+kinases&doi=10.1021%2Fml500355x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fml500355x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500355x%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DSpiliotopoulos%26aufirst%3DD.%26aulast%3DRajendran%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%2BD.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DStructural%2520analysis%2520of%2520the%2520binding%2520of%2520type%2520I%252C%2520I1%252F2%252C%2520and%2520II%2520Inhibitors%2520to%2520Eph%2520tyrosine%2520kinases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D79%26epage%3D83%26doi%3D10.1021%2Fml500355x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Nagashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shumway, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathyanarayanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolinski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilhack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiznerowicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klippel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobkova, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blume-Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northrup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, J. N.</span><span> </span><span class="NLM_article-title">Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">6433</span><span class="NLM_x">–</span> <span class="NLM_lpage">6448</span><span class="refDoi"> DOI: 10.1074/jbc.M110.156463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1074%2Fjbc.M110.156463" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=6433-6448&author=K.+Nagashimaauthor=S.+D.+Shumwayauthor=S.+Sathyanarayananauthor=A.+H.+Chenauthor=B.+Dolinskiauthor=Y.+Xuauthor=H.+Keilhackauthor=T.+Nguyenauthor=M.+Wiznerowiczauthor=L.+Liauthor=B.+A.+Lutterbachauthor=A.+Chiauthor=C.+Paweletzauthor=T.+Allisonauthor=Y.+Yanauthor=S.+K.+Munshiauthor=A.+Klippelauthor=M.+Krausauthor=E.+V.+Bobkovaauthor=S.+Deshmukhauthor=Z.+Xuauthor=U.+Muellerauthor=A.+A.+Szewczakauthor=B.+S.+Panauthor=V.+Richonauthor=R.+Pollockauthor=P.+Blume-Jensenauthor=A.+Northrupauthor=J.+N.+Andersen&title=Genetic+and+pharmacological+inhibition+of+PDK1+in+cancer+cells%3A+characterization+of+a+selective+allosteric+kinase+inhibitor&doi=10.1074%2Fjbc.M110.156463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.156463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.156463%26sid%3Dliteratum%253Aachs%26aulast%3DNagashima%26aufirst%3DK.%26aulast%3DShumway%26aufirst%3DS.%2BD.%26aulast%3DSathyanarayanan%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DA.%2BH.%26aulast%3DDolinski%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DWiznerowicz%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DChi%26aufirst%3DA.%26aulast%3DPaweletz%26aufirst%3DC.%26aulast%3DAllison%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DKlippel%26aufirst%3DA.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DBobkova%26aufirst%3DE.%2BV.%26aulast%3DDeshmukh%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DMueller%26aufirst%3DU.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DPan%26aufirst%3DB.%2BS.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DPollock%26aufirst%3DR.%26aulast%3DBlume-Jensen%26aufirst%3DP.%26aulast%3DNorthrup%26aufirst%3DA.%26aulast%3DAndersen%26aufirst%3DJ.%2BN.%26atitle%3DGenetic%2520and%2520pharmacological%2520inhibition%2520of%2520PDK1%2520in%2520cancer%2520cells%253A%2520characterization%2520of%2520a%2520selective%2520allosteric%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D6433%26epage%3D6448%26doi%3D10.1074%2Fjbc.M110.156463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kim, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canning, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandinova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2145</span><span class="NLM_x">–</span> <span class="NLM_lpage">2150</span><span class="refDoi"> DOI: 10.1021/cb400430t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400430t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFyhsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2145-2150&author=H.+G.+Kimauthor=L.+Tanauthor=E.+L.+Weisbergauthor=F.+Liuauthor=P.+Canningauthor=H.+G.+Choiauthor=S.+A.+Ezellauthor=H.+Wuauthor=Z.+Zhaoauthor=J.+Wangauthor=A.+Mandinovaauthor=J.+D.+Griffinauthor=A.+N.+Bullockauthor=Q.+Liuauthor=S.+W.+Leeauthor=N.+S.+Gray&title=Discovery+of+a+potent+and+selective+DDR1+receptor+tyrosine+kinase+inhibitor&doi=10.1021%2Fcb400430t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Kim, Hyung-Gu; Tan, Li; Weisberg, Ellen L.; Liu, Feiyang; Canning, Peter; Choi, Hwan Geun; Ezell, Scott A.; Wu, Hong; Zhao, Zheng; Wang, Jinhua; Mandinova, Anna; Griffin, James D.; Bullock, Alex N.; Liu, Qingsong; Lee, Sam W.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2145-2150</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The DDR1 receptor tyrosine kinase is activated by matrix collagens and has been implicated in numerous cellular functions such as proliferation, differentiation, adhesion, migration, and invasion.  Here we report the discovery of a potent and selective DDR1 inhibitor, DDR1-IN-1, and present the 2.2 Å DDR1 co-crystal structure.  DDR1-IN-1 binds to DDR1 in the DFG-out' conformation and inhibits DDR1 autophosphorylation in cells at submicromolar concns. with good selectivity as assessed against a panel of 451 kinases measured using the KinomeScan technol.  We identified a mutation in the hinge region of DDR1, G707A, that confers >20-fold resistance to the ability of DDR1-IN-1 to inhibit DDR1 autophosphorylation and can be used to establish what pharmacol. is DDR1-dependent.  A combinatorial screen of DDR1-IN-1 with a library of annotated kinase inhibitors revealed that inhibitors of PI3K and mTOR such as GSK2126458 potentiate the antiproliferative activity of DDR1-IN-1 in colorectal cancer cell lines.  DDR1-IN-1 provides a useful pharmacol. probe for DDR1-dependent signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAGEEijNuQNLVg90H21EOLACvtfcHk0lgz7X49MfJ8uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFyhsbbE&md5=ed0921658bbf54c35a2246d63968adb3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fcb400430t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400430t%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BG.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DEzell%26aufirst%3DS.%2BA.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMandinova%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520DDR1%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D2145%26epage%3D2150%26doi%3D10.1021%2Fcb400430t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.18632/oncotarget.10037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.18632%2Foncotarget.10037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+Liuauthor=B.+Wangauthor=Q.+Wangauthor=Z.+Qiauthor=C.+Chenauthor=L.-L.+Kongauthor=J.-Y.+Chenauthor=X.+Liuauthor=A.+Wangauthor=C.+Huauthor=W.+Wangauthor=H.+Wangauthor=F.+Wuauthor=Y.+Ruanauthor=S.+Qiauthor=J.+Liuauthor=F.+Zouauthor=Z.+Huauthor=W.+Wangauthor=L.+Wangauthor=S.+Zhangauthor=C.-H.+Yunauthor=Z.+Zhaiauthor=J.+Liuauthor=Q.+Liu&title=Discovery+and+characterization+of+a+novel+potent+type+II+native+and+mutant+BCR-ABL+inhibitor+%28CHMFL-074%29+for+Chronic+Myeloid+Leukemia+%28CML%29&doi=10.18632%2Foncotarget.10037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10037%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DL.-L.%26aulast%3DChen%26aufirst%3DJ.-Y.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DRuan%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DZhai%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520novel%2520potent%2520type%2520II%2520native%2520and%2520mutant%2520BCR-ABL%2520inhibitor%2520%2528CHMFL-074%2529%2520for%2520Chronic%2520Myeloid%2520Leukemia%2520%2528CML%2529%26jtitle%3DOncotarget%26date%3D2016%26doi%3D10.18632%2Foncotarget.10037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lglgr1p2v25qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Williams, L. T.</span><span> </span><span class="NLM_article-title">Signal transduction by the platelet-derived growth factor receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">243</span><span class="NLM_x">, </span> <span class="NLM_fpage">1564</span><span class="NLM_x">–</span> <span class="NLM_lpage">1570</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1989&pages=1564-1570&author=L.+T.+Williams&title=Signal+transduction+by+the+platelet-derived+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DL.%2BT.%26atitle%3DSignal%2520transduction%2520by%2520the%2520platelet-derived%2520growth%2520factor%2520receptor%26jtitle%3DScience%26date%3D1989%26volume%3D243%26spage%3D1564%26epage%3D1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Torres, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bill, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghadimi, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolshakov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belousov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lev, D.</span><span> </span><span class="NLM_article-title">Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3943</span><span class="NLM_x">–</span> <span class="NLM_lpage">3955</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1158%2F1078-0432.CCR-11-0193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=21540237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=3943-3955&author=K.+E.+Torresauthor=Q.+S.+Zhuauthor=K.+Billauthor=G.+Lopezauthor=M.+P.+Ghadimiauthor=X.+Xieauthor=E.+D.+Youngauthor=J.+Liuauthor=T.+Nguyenauthor=S.+Bolshakovauthor=R.+Belousovauthor=S.+Wangauthor=G.+Lahatauthor=J.+Liuauthor=B.+Hernandezauthor=A.+J.+Lazarauthor=D.+Lev&title=Activated+MET+is+a+molecular+prognosticator+and+potential+therapeutic+target+for+malignant+peripheral+nerve+sheath+tumors&doi=10.1158%2F1078-0432.CCR-11-0193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors</span></div><div class="casAuthors">Torres, Keila E.; Zhu, Quan-Sheng; Bill, Katelynn; Lopez, Gonzalo; Ghadimi, Markus P.; Xie, Xian-Biao; Young, Eric D.; Liu, Jue-Hui; Nguyen, Theresa; Bolshakov, Svetlana; Belousov, Roman; Wang, Sui-Zhau; Lahat, Guy; Liu, Jun; Hernandez, Belinda; Lazar, Alexander J.; Lev, Dina</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3943-3955</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MET signaling has been suggested a potential role in malignant peripheral nerve sheath tumors (MPNST).  Here, MET function and blockade were preclinically assessed.  Exptl. Design: Expression levels of MET, its ligand hepatocyte growth factor (HGF), and phosphorylated MET (pMET) were examd. in a clin. annotated MPNST tissue microarray (TMA) incorporating univariable and multivariable statistical analyses.  Human MPNST cells were studied in vitro and in vivo; Western blot (WB) and ELISA were used to evaluate MET and HGF expression, activation, and downstream signaling.  Cell culture assays tested the impact of HGF-induced MET activation and anti-MET-specific siRNA inhibition on cell proliferation, migration, and invasion; in vivo gel-foam assays were used to evaluate angiogenesis.  Cells stably transduced with anti-MET short hairpin RNA (shRNA) constructs were tested for growth and metastasis in severe combined immunodeficient (SCID) mice.  The effect of the tyrosine kinase inhibitor XL184 (Exelixis) targeting MET/VEGFR2 (vascular endothelial growth factor receptor 2) on local and metastatic MPNST growth was examd. in vivo.  All three markers were expressed in MPNST human samples; pMET expression was an independent prognosticator of poor patient outcome.  Human MPNST cell lines expressed MET, HGF, and pMET.  MET activation increased MPNST cell motility, invasion, angiogenesis, and induced matrix metalloproteinase-2 (MMP2) and VEGF expression; MET knockdown had inverse effects in vitro and markedly decreased local and metastatic growth in vivo.  XL184 abrogated human MPNST xenograft growth and metastasis in SCID mice.  Informative prognosticators and novel therapies are crucially needed to improve MPNST management and outcomes.  We show an important role for MET in MPNST, supporting continued investigation of novel anti-MET therapies in this clin. context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Nx2rtKdYt7Vg90H21EOLACvtfcHk0lglgr1p2v25qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKgsbg%253D&md5=494fe0a3b10bf230db323396a5f57211</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0193%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DK.%2BE.%26aulast%3DZhu%26aufirst%3DQ.%2BS.%26aulast%3DBill%26aufirst%3DK.%26aulast%3DLopez%26aufirst%3DG.%26aulast%3DGhadimi%26aufirst%3DM.%2BP.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DYoung%26aufirst%3DE.%2BD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DBolshakov%26aufirst%3DS.%26aulast%3DBelousov%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLahat%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DLev%26aufirst%3DD.%26atitle%3DActivated%2520MET%2520is%2520a%2520molecular%2520prognosticator%2520and%2520potential%2520therapeutic%2520target%2520for%2520malignant%2520peripheral%2520nerve%2520sheath%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D3943%26epage%3D3955%26doi%3D10.1158%2F1078-0432.CCR-11-0193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Valiathan, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitinger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleer, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, R.</span><span> </span><span class="NLM_article-title">Discoidin domain receptor tyrosine kinases: new players in cancer progression</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">321</span><span class="refDoi"> DOI: 10.1007/s10555-012-9346-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1007%2Fs10555-012-9346-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=22366781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=295-321&author=R.+R.+Valiathanauthor=M.+Marcoauthor=B.+Leitingerauthor=C.+G.+Kleerauthor=R.+Fridman&title=Discoidin+domain+receptor+tyrosine+kinases%3A+new+players+in+cancer+progression&doi=10.1007%2Fs10555-012-9346-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discoidin domain receptor tyrosine kinases: new players in cancer progression</span></div><div class="casAuthors">Valiathan, Rajeshwari R.; Marco, Marta; Leitinger, Birgit; Kleer, Celina G.; Fridman, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">295-321</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Almost all human cancers display dysregulated expression and/or function of one or more receptor tyrosine kinases (RTKs).  The strong causative assocn. between altered RTK function and cancer progression has been translated into novel therapeutic strategies that target these cell surface receptors in cancer.  Yet, the full spectrum of RTKs that may alter the oncogenic process is not completely understood.  Accumulating evidence suggests that a unique set of RTKs known as the discoidin domain receptors (DDRs) play a key role in cancer progression by regulating the interactions of tumor cells with their surrounding collagen matrix.  The DDRs are the only RTKs that specifically bind to and are activated by collagen.  DDRs control cell and tissue homeostasis by acting as collagen sensors, transducing signals that regulate cell polarity, tissue morphogenesis, and cell differentiation.  In cancer, DDRs are hijacked by tumor cells to disrupt normal cell-matrix communication and initiate pro-migratory and pro-invasive programs.  Importantly, several cancer types exhibit DDR mutations, which are thought to alter receptor function and contribute to cancer progression.  Other evidence suggests that the actions of DDRs in cancer are complex, either promoting or suppressing tumor cell behavior in a DDR type/isoform specific- and context-dependent manner.  Thus, there is still a considerable gap in our knowledge of DDR actions in cancer tissues.  This review summarizes and discusses the current knowledge on DDR expression and function in cancer.  It is hoped that this effort will encourage more research into these poorly understood but unique RTKs, which have the potential of becoming novel therapeutic targets in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6IvVtcaWbw7Vg90H21EOLACvtfcHk0lijIqfBD_73CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFajs7c%253D&md5=da63c7783212d348b80aeaef7d90094c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs10555-012-9346-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-012-9346-z%26sid%3Dliteratum%253Aachs%26aulast%3DValiathan%26aufirst%3DR.%2BR.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DLeitinger%26aufirst%3DB.%26aulast%3DKleer%26aufirst%3DC.%2BG.%26aulast%3DFridman%26aufirst%3DR.%26atitle%3DDiscoidin%2520domain%2520receptor%2520tyrosine%2520kinases%253A%2520new%2520players%2520in%2520cancer%2520progression%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2012%26volume%3D31%26spage%3D295%26epage%3D321%26doi%3D10.1007%2Fs10555-012-9346-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Pollard, J. W.</span><span> </span><span class="NLM_article-title">Trophic macrophages in development and disease</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nri2528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1038%2Fnri2528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=19282852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=259-270&author=J.+W.+Pollard&title=Trophic+macrophages+in+development+and+disease&doi=10.1038%2Fnri2528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Trophic macrophages in development and disease</span></div><div class="casAuthors">Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Specialized phagocytes are found in the most primitive multicellular organisms.  Their roles in homeostasis and in distinguishing self from non-self have evolved with the complexity of organisms and their immune systems.  Equally important, but often overlooked, are the roles of macrophages in tissue development.  As discussed in this Review, these include functions in branching morphogenesis, neuronal patterning, angiogenesis, bone morphogenesis and the generation of adipose tissue.  In each case, macrophage depletion impairs the formation of the tissue and compromises its function.  I argue that in several diseases, the unrestrained acquisition of these developmental macrophage functions exacerbates pathol.  For example, macrophages enhance tumor progression and metastasis by affecting tumor-cell migration and invasion, as well as angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR03M07hzbU7Vg90H21EOLACvtfcHk0lijIqfBD_73CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D&md5=d29685d4cbb8d8bdd296f8b8ff869d36</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnri2528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2528%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTrophic%2520macrophages%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D259%26epage%3D270%26doi%3D10.1038%2Fnri2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rossato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiesko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedani, A.</span><span> </span><span class="NLM_article-title">Probing small-molecule binding to cytochrome P450 2D6 and 2C9: an in silico protocol for generating toxicity alerts</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2088</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span><span class="refDoi"> DOI: 10.1002/cmdc.201000358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1002%2Fcmdc.201000358" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=2088-2101&author=G.+Rossatoauthor=B.+Ernstauthor=M.+Smieskoauthor=M.+Spreaficoauthor=A.+Vedani&title=Probing+small-molecule+binding+to+cytochrome+P450+2D6+and+2C9%3A+an+in+silico+protocol+for+generating+toxicity+alerts&doi=10.1002%2Fcmdc.201000358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000358%26sid%3Dliteratum%253Aachs%26aulast%3DRossato%26aufirst%3DG.%26aulast%3DErnst%26aufirst%3DB.%26aulast%3DSmiesko%26aufirst%3DM.%26aulast%3DSpreafico%26aufirst%3DM.%26aulast%3DVedani%26aufirst%3DA.%26atitle%3DProbing%2520small-molecule%2520binding%2520to%2520cytochrome%2520P450%25202D6%2520and%25202C9%253A%2520an%2520in%2520silico%2520protocol%2520for%2520generating%2520toxicity%2520alerts%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D2088%26epage%3D2101%26doi%3D10.1002%2Fcmdc.201000358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Word, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span> </span><span class="NLM_article-title">Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation 1</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">1735</span><span class="NLM_x">–</span> <span class="NLM_lpage">1747</span><span class="refDoi"> DOI: 10.1006/jmbi.1998.2401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=10.1006%2Fjmbi.1998.2401" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=1735-1747&author=J.+M.+Wordauthor=S.+C.+Lovellauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=Asparagine+and+glutamine%3A+using+hydrogen+atom+contacts+in+the+choice+of+side-chain+amide+orientation+1&doi=10.1006%2Fjmbi.1998.2401"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1998.2401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1998.2401%26sid%3Dliteratum%253Aachs%26aulast%3DWord%26aufirst%3DJ.%2BM.%26aulast%3DLovell%26aufirst%3DS.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DAsparagine%2520and%2520glutamine%253A%2520using%2520hydrogen%2520atom%2520contacts%2520in%2520the%2520choice%2520of%2520side-chain%2520amide%2520orientation%25201%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D285%26spage%3D1735%26epage%3D1747%26doi%3D10.1006%2Fjmbi.1998.2401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Dobler, M.</span>BioX, a Versatile Molecular-Modeling Software; <span class="NLM_publisher-name">Biographics Laboratory 3R</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.biograf.ch/index.php?id=software" class="extLink">http://www.biograf.ch/index.php?id=software</a> (updated Nov 8, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Dobler&title=BioX%2C+a+Versatile+Molecular-Modeling+Software"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDobler%26aufirst%3DM.%26jtitle%3DBioX%252C%2520a%2520Versatile%2520Molecular-Modeling%2520Software%26pub%3DBiographics%2520Laboratory%25203R%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Vedani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huhta, D. W.</span><span> </span><span class="NLM_article-title">A new force field for modeling metalloproteins</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">4759</span><span class="NLM_x">–</span> <span class="NLM_lpage">4767</span><span class="refDoi"> DOI: 10.1021/ja00168a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00168a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;key=1%3ACAS%3A528%3ADyaK3cXktVaqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=1990&pages=4759-4767&author=A.+Vedaniauthor=D.+W.+Huhta&title=A+new+force+field+for+modeling+metalloproteins&doi=10.1021%2Fja00168a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A new force field for modeling metalloproteins</span></div><div class="casAuthors">Vedani, Angelo; Huhta, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4759-67</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">A force field for the simulation of metalloproteins features a new potential function for modeling metal-ligand interactions.  This function includes s variables the metal-ligand sepns., the symmetry at the metal center, directionality of the metal-ligand bonds, ligand-metal charge transfer, and (for transition-metal ions) ligand-field stabilization.  The function was developed based on the anal. of accurate small-mol. crystal structures retrieved from the Cambridge Structural Database and incorporated into the mol. mechanics program Yeti which also includes directional terms for H-bonds and salt linkages in its force field energy expression.  The program then was used to model details of metal-coordination, H-bond network formation and protein-solvent interactions in native, complexed, and Co(II)-substituted human carbonic anhydrase I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMppUxyYGE4rVg90H21EOLACvtfcHk0lg2uaJFB_nMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktVaqsLs%253D&md5=107e319b852d73f13359ea3f40f99f14</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja00168a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00168a021%26sid%3Dliteratum%253Aachs%26aulast%3DVedani%26aufirst%3DA.%26aulast%3DHuhta%26aufirst%3DD.%2BW.%26atitle%3DA%2520new%2520force%2520field%2520for%2520modeling%2520metalloproteins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1990%26volume%3D112%26spage%3D4759%26epage%3D4767%26doi%3D10.1021%2Fja00168a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HU9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HU9','PDB','5HU9'); return false;">PDB: 5HU9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46','PDB','1T46'); return false;">PDB: 1T46</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i72"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01290">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_82617"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01290">10.1021/acs.jmedchem.6b01290</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">DiscoveRx’s KINOMEscan selectivity profiling data of compound <b>34</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01290/suppl_file/jm6b01290_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01290/suppl_file/jm6b01290_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01290/suppl_file/jm6b01290_si_001.pdf">jm6b01290_si_001.pdf (166.81 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01290/suppl_file/jm6b01290_si_002.csv">jm6b01290_si_002.csv (6.21 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01290&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01290%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-1%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01290" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0e255fc3aa336","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
